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ABSTRACT 
Mitochondria are energy-producing organelles present in eukaryotic cells. Energy as adenosine 
triphosphate (ATP) is produced at the end of a series of electron transfers called the electron 
transport chain (ETC). Such a highly coordinated and regulated series of electron transfer 
reactions give rise to a small percentage of electron leakage which, by the subsequent reduction 
of molecular oxygen, produce superoxide anions (O2
.-). These anions initiate the production of 
additional highly reactive oxygen-containing radicals commonly known as reactive oxygen 
species (ROS). Although cells are equipped with endogenous antioxidant systems to minimize 
ROS accumulation, these endogenous defense systems become inadequate when ROS generation 
is increased. When ROS production occurs in excess, the cell is said to be under oxidative stress. 
Unchecked ROS production causes damage to cellular macromolecules, which in turn leads to 
cell death. Dysfunctional mitochondria and subsequent cell degeneration are a common cause of 
neurodegenerative diseases such as Friedreich’s ataxia (FRDA) and Alzheimer’s disease (AD). 
Therefore, targeting the mitochondria by neuroprotective drugs is imperative for the treatment of 
such diseases. In Chapter 1, the functioning of the ETC is described. Moreover, excessive ROS 
production and its consequences are also described. 
FRDA is a progressive neurodegenerative disease caused by insufficient expression of frataxin 
(FXN). FXN is instrumental in the assembly of iron-sulfur clusters, which in turn are critical for 
the functioning of the ETC enzyme complexes. Therapeutic agents which, in addition to being 
antioxidants also increase FXN, can be good drugs to counter FRDA. In Chapter 2, the synthesis 
of phenothiazine analogues are described. Moreover, their efficacy as antioxidants and their 
ability to increase FXN are described. Finally, the synthesis of a reduced salt form of one 
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analogue and its ability to cross the blood brain barrier (BBB) in mouse models of the disease is 
also described.  
In Chapter 3, to discover potent neuroprotective drugs, a pair of regioisomeric benzoquinone 
analogues has been synthesized. The compounds were tested for their efficacy as antioxidants. 
Additionally, two pyrimidinol based redox cores were analyzed electrochemically to enable a 
better understanding of the mechanism of action of the multifunctional radical quencher (MRQ) 
class of antioxidants.       
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CHAPTER 1 
     INTRODUCTION 
The mitochondrion is an energy producing organelle present in all eukaryotic cells.1 
Mitochondria occupy a considerable portion of the cytoplasmic volume in these cells, and they 
have been instrumental in the evolution of complex animals.1 Without mitochondria, animal cells 
would have relied heavily on anaerobic glycolysis to satisfy their energy needs.1 Such a 
phenomenon would likely have hampered their evolution because ATP produced by 
mitochondria is 15 times greater than that produced by glycolysis alone.1 
The oxidation of food-derived molecules in the cytosol produces pyruvate and fatty acids.1 
Pyruvate results from the oxidation of glucose and other sugars whereas fatty acids are produced 
by the oxidation of fats.1 Mitochondria are capable of using both pyruvate and fatty acids as 
fuel.1 Both are transported across the inner mitochondrial membrane into the mitochondrial 
matrix.1 In the matrix, these molecules are converted to acetyl CoA by enzymes.1 Acetyl CoA is 
oxidized in the citric acid cycle, forming the high energy electron carriers NADH and FADH2.
1 
The electrons carried by these activated carriers are transferred to the inner mitochondrial 
membrane where they enter the ETC.1 These electrons finally combine with molecular oxygen at 
the end of the ETC.1 The oxidative energy released by the transfer of electrons through the ETC 
is utilized later for the phosphorylation of ADP to produce ATP.1 Because oxidation is combined 
with phosphorylation, this process is called oxidative phosphorylation (OX-PHOS).1 
Specifically, the inner mitochondrial membrane contains a series of five embedded enzyme 
complexes (complex I or NADH dehydrogenase; complex II or succinate dehydrogenase; 
complex III or cytochrome bc1 complex; complex IV or cytochrome c oxidase; complex V or 
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ATP synthase) and two mobile electron carriers (ubiquinone located between complexes I/II and 
III, and cytochrome c located between complex III and IV).2 Complexes I through IV comprise 
of the ETC whereas complex V is responsible for the phosphorylation of ADP.2  
Initially, complex I catalyzes the transfer of two electrons from NADH to ubiquinone by means 
of FMN and Fe-S clusters.3 Simultaneously, four protons are pumped from the mitochondrial 
matrix to the intermembrane space through the same complex.3 Similarly, complex II catalyzes 
the transfer of electrons from FADH2 to ubiquinone.
3 However, proton pumping to the 
intermembrane space does not result from the reduction of complex II.3 Two electrons are 
transported to complex III from ubiquinone.3 The transport of electrons through complex III 
results in another proton pumping event in which two protons are transported into the 
intermembrane space.4 Thereafter, two electrons are transported from complex III to the second 
electron-carrier cytochrome c.3 Cytochrome c transports electrons to complex IV.3 The third and 
final proton pumping event occurs at complex IV.3 The acceptance of electrons by complex IV 
and the reduction of molecular O2 to H2O results in four protons being pumped to the 
intermembrane space.4 The ten protons that are pumped into the intermembrane space enable the 
mitochondria to harness the energy released by the series of electron transfer events that occurs 
in the ETC.3 A generalized view of the ETC is shown in Figure 1.1.    
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Figure 1.1. A generalized view of the ETC. The stoichiometry of electrons mentioned in the text 
have been omitted in the diagram. Complexes I-V are labelled. Mobile electron carrier 
ubiquinone is labelled as ‘U’ and cytochrome c is labelled as ‘C’.   
Specifically, the protons in the intermembrane space create an electrochemical proton gradient.1 
This gradient is a combination of a pH gradient and a voltage gradient (Figure 1.2).1 Due to the 
pumping of protons, the pH of the intermembrane space is lower (pH ~ 7) compared to that of 
the matrix (pH ~ 8).1 This difference in concentration enables the pumping of protons into the 
matrix by ATP synthase, since the outside of the inner mitochondrial membrane is positively 
polarized whereas the inside is negatively polarized.1     
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Figure 1.2. The two components of the electrochemical proton gradient comprising of a) pH 
gradient and b) potential gradient. 
Complex V or ATP synthase is a multi-subunit protein having a mass in excess of 500,000 
Daltons.1 The flow of protons back into the matrix is mediated through a small pore in the 
enzyme complex.1 The potential energy released by the proton flow produces a mechanical 
movement in the enzyme complex.1 That movement in turn causes conformational changes in the 
binding sites in the enzyme.1 These conformational changes cause the binding of ADP and 
inorganic phosphate.1 Phosphorylation of ADP produces ATP, which is then released as the final 
product.1 Approximately three ATP molecules are produced for each 10 protons pumped into the 
intermembrane space.5,6 
The mitochondrial ETC is responsible for consuming the bulk of the oxygen present in cells.7,8 
The electron transfers occurring within the inner mitochondrial membrane is highly coordinated 
between the mitochondrial complexes.1 Nonetheless, electron leakage occurs as a by-product of 
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this highly synchronized electron transport process.7,8 The leakage occurs mainly from 
complexes I and III.3 As a result, molecular oxygen in the matrix gets partially reduced initially, 
producing ROS in the form of superoxide anion (O2
.-).7,8 At low concentrations in normally 
respiring mitochondria, ROS is important to the cell because it is used as a defense against 
pathogens and also for signaling purposes.9-11 ROS is tightly regulated in the mitochondria to 
keep its concentration at the basal level.12-16  
Specifically, as shown in Figure 1.3, the regulation of O2
.- begins with its conversion to hydrogen 
peroxide (H2O2).
12-16 The reaction is a dismutation reaction and is carried out in presence of the 
endogenous or natural enzymatic antioxidant superoxide dismutase (SOD).12-16 The resulting 
H2O2 is further converted to non-toxic molecules by two other natural enzymatic antioxidants, 
namely catalase and glutathione peroxidase.12-16 Thus, excess ROS is detoxified by the natural 
defense system inside the mitochondria. 
 
Figure 1.3. The tight regulation of ROS by natural enzymatic antioxidants.  
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However, in dysfunctional mitochondria ROS is over-produced.12-16 In such a situation, the 
natural enzymatic antioxidants are not sufficient enough to counter the excess ROS 
production.12-16 Consequently, the excess of both O2
.- and H2O2 become detrimental to cell 
health.12-16 H2O2 undergoes the Fenton reaction (Figure 1.4) with metallic iron in the cells to 
produce another radical species, the hydroxyl radical (OH
.
).12-16 O2
.- reacts directly with the nitric 
oxide radical (NO.) to produce another ROS, peroxynitrite (ONOO-).12-16 Both OH
.
 and ONOO- 
are highly reactive.12-16 Both these species react readily with cellular macromolecules such as 
mitochondrial DNA, lipids and proteins, and cause damage which ultimately leads to cell 
death.12-16  
 
Figure 1.4. The Fenton reaction. 
The manner in which radical species such as OH
.
 causes lipid damage is shown in Figure 1.5 as a 
set of reactions commonly known as lipid peroxidation.17-19  
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Figure 1.5. Reactions involved in lipid peroxidation.  
ROS in the form of a hydroxyl radical abstracts a hydrogen atom from the lipid membrane of a 
cell.17-19 Following the chain initiation step, molecular oxygen causes peroxidation of the lipid 
molecule in a diffusion controlled reaction.17-19 The lipid peroxide radical can then abstract a 
hydrogen atom from another lipid molecule, which serves as the chain propagation step.17-19 
Thus, one hydroxyl radical is capable of causing numerous lipid peroxidation reactions. This 
continuous chain of peroxidation reactions causes numerous lesions in the lipid membrane 
ultimately leading to a dysfunctional mitochondrion and cell.17-19 
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There are certain natural non-enzymatic antioxidants, apart from the previously mentioned 
enzymatic antioxidants, which are found commonly in our daily diets and serve as another line of 
defense against ROS mediated cell damage.20-30 For example, α-tocopherol (commonly vitamin 
E) is found in green leafy vegetables like broccoli and kale.20-30 Moreover, L-ascorbic 
(commonly vitamin C), which plays a pivotal role in α-tocopherol antioxidant recycling, is found 
in citrus fruits like oranges and grapes (Figure 1.6).20-30     
 
Figure 1.6. Structures of α-tocopherol and L-ascorbic acid.     
α-Tocopherol acts as an antioxidant by inhibiting the lipid peroxidation chain reaction as shown 
in Figure 1.7.31-33 The phenolic -OH functional group is critical for the antioxidant activity.31-33 
Donation of a hydrogen atom from α-tocopherol quenches the lipid peroxide radical, thereby 
suppressing further lipid radical generation.31-33 The α-tocopherol radical that forms doesn’t act 
as a reactive radical itself because of its resonance stabilization.31-33 Moreover, α-tocopherol is 
able to act in a catalytic fashion because of the recycling capability of L-ascorbic acid.31-33 The 
vitamin C radical generated as a result of the recycling reaction is also recycled in turn by 
NADH which is ubiquitously present in cells.31-33  
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Figure 1.7. α-Tocopherol antioxidant activity and its regeneration by vitamin C.  
When ROS production occurs in excess, the cell is said to be in a state of oxidative stress.34-40 A 
cell under such stress can undergo apoptosis (cell death or degeneration).34-40 Since energy in the 
form of ATP is a major requirement for numerous cellular functions and since mitochondria are 
the major producers of ATP, functional mitochondria are imperative for cell health. It has indeed 
been found that oxidative stress, excess ROS and diminished ATP are common features in the 
pathologies of neurodegenerative diseases such as FRDA, AD, PD and ALS.34-40  
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Friedreich’s ataxia is a progressive autosomal recessive neurodegenerative disease primarily 
caused by insufficient expression of the mitochondrial protein frataxin.41 Early symptoms of the 
disease include impaired muscle coordination and movement problems.42-43 At a later stage, the 
disease can lead to Scoliosis (curvature of the spine), hypertrophic cardiomyopathy (enlargement 
of the heart) and cardiac failure.42-43 FRDA currently has no cure.42-43 Physical and speech 
therapy are available to provide temporary relief to the patient.42-43 Dysfunctional mitochondria, 
ROS over-production, oxidative stress and consequently death of neuronal cells 
(neurodegeneration) have been implicated in the pathology of this disease.41 Briefly, suppression 
of FXN expression hampers iron metabolism.44 As a result, proper assembly of iron-sulfur (Fe-S) 
clusters in the mitochondrial ETC enzyme complexes are hindered.44 Moreover, owing to iron 
accumulation in the mitochondria, the probability of Fenton chemistry increases drastically.45 
Consequently, enhanced electron leakage occurs from these complexes, leading to oxidative 
stress via the Fenton reaction.45  
Alzheimer’s disease is a progressive neurodegenerative disease characterized by severe memory 
loss especially in the aged population (65 years and above).46,47 Some medications belonging to 
the class of cholinesterase inhibitors are prescribed by doctors to lessen the symptoms associated 
with the disease.46,47 However, the disease is currently incurable.46,47 Amyloid-β peptide 
accumulation at the synapse between nerve cells followed by ROS over-production and oxidative 
stress have been shown to be involved in the pathology of the disease.45 Briefly, metal ions (Fe3+, 
Cu2+ and Zn2+) accumulate in the brain with age.45 These metals induce the aggregation and 
precipitation of amyloid-β peptides at the synapse between nerve cells and they are commonly 
called amyloid plaques.45 Fe3+ and Cu2+ bound to these plaques induce the formation of 
excessive hydrogen peroxide.45 The drastic increase in hydrogen peroxide facilitates oxidative 
11 
 
stress via the Fenton reaction.45 In addition, neurofibrillar Tau protein which stabilizes axonal 
microtubules and aids nerve cell signaling, forms aggregates in AD.48 In its aggregated form, 
Tau is unable to support the transportation of nerve impulses which is a major cause of AD.48 
Further pathology associated with AD includes reduction in mitochondrial complex IV activity 
and a decrease in the expression of the COX subunits encoded in mitochondrial and nuclear 
DNA.49  
Parkinson’s disease in another progressive neurodegenerative disease characterized by tremors in 
the hands, arms, legs and jaws, ‘bradykinesia’ or slowness of movement, rigidity and stiffness of 
the limbs and trunk, postural instability, impaired balance and coordination.50,51 Surgical 
treatments such as deep brain stimulation (DBS) or medications such Levodopa (a dopamine 
prodrug) are prescribed by doctors.50,51 However, these treatments have their disadvantages and 
there is currently no cure for the disease.50,51 Oxidative stress, protein (α-synuclein) aggregation 
and neurodegeneration have been identified in the disease etiology.45 Briefly, mutations in the 
protein α-synuclein, which is ubiquitously expressed in the brain, caused unwanted release of the 
neurotransmitter dopamine.45 Dopamine’s interaction with excess metals Fe3+ and Cu2+ causes 
increased production of hydrogen peroxide, thereby leading to oxidative stress via the Fenton 
reaction.45      
Amyotrophic lateral sclerosis is another progressive neurodegenerative disease characterized by 
muscle weakness and it impacts physical function.52,53 Some medications are available which 
slow disease progression but have associated side effects.52,53 Physical and speech therapy are 
also available to abate the symptoms but understandably only a temporary solution.52,53 This 
disease is also currently incurable.52,53 Once again, oxidative stress, aggregation of the protein 
Cu/ZnSOD and subsequent motor neuron degeneration characterize the disease pathology.45 
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Briefly, accumulation of metal ions particularly Cu2+, cause binding of the metal ions to low 
affinity binding sites of Cu/ZnSOD.45 These low-affinity bound Cu2+ cause hydrogen peroxide 
production and generation of oxidative stress via Fenton reaction.45 Therefore, it is clear that 
oxidative stress has a major involvement in the pathologies of the above mentioned neurological 
diseases.  
Due to the fact that ROS is deeply involved in all four of the above mentioned mitochondrial or 
neurodegenerative diseases, it is quite natural to think of antioxidant therapy to counter disease 
progression. Antioxidants act by quenching ROS (Figure 1.8).31-33 The high antioxidant potency 
of the natural antioxidant α-tocopherol is due to the phenolic -OH functional group.31-33 
 
Figure 1.8. Mode of action of phenolic -OH containing antioxidants.  
Moreover, coenzyme Q10 or ubiquinone is a well-documented natural antioxidant when in its 
reduced form (Figure 1.9).7,44  
 
Figure 1.9. The reduction-oxidation cycle of ubiquinone.   
Not surprisingly, artificial or unnatural antioxidants having the coenzyme Q10 type functionality 
are well established in the medicinal chemistry literature (Figure 1.10).54-56  
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Figure 1.10. Unnatural antioxidants belonging to the coenzyme Q10 category. 
 
In addition, medicinal chemists, in the Hecht laboratory have also synthesized compounds with a 
phenolic -OH functional group (Figure 1.10) denoted as MRQs, to assess their antioxidant 
potential.57 
 
Figure 1.11. MRQs based on a pyridinol scaffold. 
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The synthetic antioxidants shown in Figures 1.10 and 1.11 displayed low-to-moderate activities 
in terms of augmenting ATP levels and maintaining mitochondrial membrane potential owing to 
reasons which are described in detail in Chapter 3, creating plenty of scope for improvement in 
terms of structure-activity relationships (SAR).57   
In this thesis, the synthesis of MRQs based on a pyrimidinol scaffold have been described in 
Chapter 3. Their biological activities tested in cultured cells have been elucidated. In addition, an 
attempt to determine the mechanism of action of MRQs in the mitochondria using cyclic 
voltammetry has been made.  
We have used MB, which is a well-known neuroprotective agent, as our lead compound. In our 
quest to augment MB’s activity while also reducing its cytotoxicity, a series of structurally 
optimized MB and MV analogues have been described in Chapter 2 of this thesis. They have 
been tested in cultured FRDA cells to assess their ability to suppress oxidative stress. Moreover, 
MB’s efficacy as an electron bypass carrier between NADH and cytochrome c is well 
documented.58 The synthesized analogues have been tested for their ability to shuttle electrons, 
bypassing lesions in the respiratory chain. Lastly, the synthesis of the reduced salt form for one 
promising analogue has been described. The reduced salt form of that analogue should enable 
study in animal models of FRDA, consequently enabling us to get an idea of its ability to cross 
the blood-brain barrier. 
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CHAPTER 2 
PHENOTHIAZINE ANALOGUES AS THERAPEUTIC AGENTS FOR FRIEDREICH’S 
ATAXIA 
2.1. Introduction 
 Dysfunctional mitochondria, over-production of ROS and consequent oxidative stress 
have been confirmed as major contributors to neurodegenerative diseases such as Friedreich’s 
ataxia and Alzheimer’s disease.41,45 FRDA is a progressive autosomal recessive 
neurodegenerative disease.41,44 It is usually caused by an expansion of the GAA trinucleotide 
repeat in the first intron of the FXN gene which suppresses the expression of the frataxin 
protein.59-63 The extent of the trinucleotide repeat expansion in FRDA has been shown to be 
inversely correlated to FXN protein expression.44 Frataxin expression from nuclear DNA occurs 
in the cytoplasm, followed by transport to the mitochondria.44 Once in the mitochondria, it 
performs vital functions as an iron chaperone protein.44 As an iron chaperone protein, its main 
function is to enable the proper assembly of Fe-S clusters inside mitochondrial ETC complexes I, 
II and III.44 Therefore, decreased frataxin expression leads to dysfunctional ETC enzyme 
complexes, which in turn cause increased electron leakage and ROS formation. Moreover, low 
levels of frataxin result in increased Fe levels, thus increasing Fenton chemistry and oxidative 
stress inside the mitochondria.45 Thus, sufficient frataxin expression is the key factor to prevent 
early onset of FRDA and also to blunt disease progression.  
MB (Figure 2.1) is an FDA approved drug for treating diseases such as methemoglobinemia and 
ifosfamide-induced encephalopathy.64-67 In addition, MB represents a potential neuroprotective 
drug for neurological diseases such as Alzheimer’s disease.68 MB has also been shown to rescue 
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heart defects in frataxin deficient FRDA models.69 Finally, research concerning the effects of 
MB in the mitochondria has shown that it can act as an electron shuttling compound by rerouting 
electrons from complex I to cytochrome c.58 Therefore, MB has the ability to maintain electron 
transport within the ETC even in the event of complex I/III dysfunction, thereby minimizing 
ROS over-production. The above observations have led us to believe that MB can serve as a 
good lead compound for realizing a therapeutic agent for the treatment of FRDA.    
 
Figure 2.1. Structures of MB and MV, which have been used as lead compounds in our research.   
MV (Figure 2.1) is a neutral phenothiazine which can be obtained by the hydrolysis of MB under 
strongly basic conditions.70 While obtained in its oxidized quinone form, MV can be reduced to 
the phenolic quinol form by mitochondrial redox centers, similar to ubiquinone (Figure 1.9). 
Consequently, it has the potential of acting as an antioxidant inside the mitochondria in the same 
manner as other phenolic -OH containing antioxidants (Figure 1.8). Therefore, we have chosen 
MV as our second lead compound. 
A series of MB analogues were synthesized, characterized and tested in biological assays (Figure 
2.2). In previous studies involving antioxidants based on a heterocyclic scaffold, it has been 
observed that a lipophilic side chain was required for the compounds to be potent suppressors of 
oxidative stress.71 The locus of oxidative stress being the mitochondrial inner membrane and the 
matrix, the need for such lipophilicity is understandable. Therefore, all the synthesized 
compounds have varied lipophilic side chains attached to an aromatic ring.  
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Figure 2.2. MB analogues synthesized, characterized and tested in biological assays.  
Again, as it is known that the mitochondrial inner membrane is positively polarized on the 
outside and negatively polarized on the inside (Figure 1.2).1 It seems likely that a compound 
having a positive charge will have more facile entry to the mitochondrial matrix.57 All the 
synthesized MB analogues have this property. 
A series of MV analogues were also synthesized, characterized and tested in biological assays 
(Figure 2.3). A disadvantage of the MB analogues could involve their hydrophilicity, owing to 
the positive charge, which could restrict their permeability across lipid membranes. As a result, 
the cellular uptake of such compounds could be problematic. We rationalized that one way of 
dealing with this problem would be by increasing the lipophilicity of our agents. Accordingly, 
we designed MV analogues as shown in Figure 2.3. The MV compounds, due to the lack of a 
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positive charge, are much more lipophilic than their corresponding MB counterparts. The MV 
analogues are also accessible in a single step from the respective MB analogues. 
   
Figure 2.3. MV analogues synthesized, characterized and tested in biological assays.  
Mitochondrial protein acetylation is an important post-translational modification.72-76 Its 
regulation by sirtuin deacetylase is necessary for functional mitochondria.72-76 Hyperacetylation 
of mitochondrial proteins have been observed in frataxin deficient mice.72-76 Moreover, sirtuin 
deacetylase inhibition as a consequence of suppression of NADH oxidation has been found to be 
the cause of such an observation.72-76 It has been shown that both rotenone (a complex I 
inhibitor) and nicotinamide (NAM, a sirtuin deacetylase inhibitor) cause mitochondrial protein 
hyperacetylation to a similar extent.72-76 Again, nicotinamide mononucleotide (NMN, an NAD+ 
precursor) has been shown to cause an increase in cellular NAD+ levels, which resulted in 
enhanced sirtuin deacetylase activity and consequent mitochondrial protein deacetylation.72-76  
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Peroxisome proliferator-activated receptor gamma (PPARγ) coactivator 1-alpha (PGC-1α) is a 
protein that plays a vital role in mitochondrial biogenesis by regulation at the transcriptional 
level.76 PGC-1α was found to be downregulated in FRDA models.76 Also, a dysfunctional PGC-
1α was confirmed in cellular and animal models of frataxin deficiency.76 Sirtuin deacetylase has 
been shown to enhance PGC-1α signaling with consequent increased mitochondrial biogenesis 
and frataxin expression.76 
Keeping these observations in mind, we have proposed a mechanism (Figure 2.4) which involves 
electron shuttling by MB in the event of a complex I inhibition by rotenone, consequent increase 
in NAD+/NADH ratio, sirtuin activation, upregulation of frataxin expression and downregulation 
of ROS. Briefly, oxidation of NADH to NAD+ causes activation of NAD+ dependent sirtuin 
deacetylase. Deacetylation of PGC-1α and its subsequent phosphorylation by 5/-adenosine 
monophosphate activated protein kinase (AMPK) results in enhanced mitobiogenesis and 
frataxin expression. Also, deacetylation of the natural enzymatic antioxidant manganese 
superoxide dismutase (MnSOD) results in the downregulation of ROS. 
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Figure 2.4. Proposed mechanism of electron shuttling by MB in the event of a dysfunctional 
electron transport from complex I to complex III.     
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Therefore, it is clear that therapeutic compounds (Figures 2.2 and 2.3) which target 
mitochondrial protein acetylation by increasing NADH oxidation and sirtuin deacetylase 
activation will be able to increase mitobiogenesis, frataxin expression and decrease ROS 
production. 
The blood-brain barrier is the junction where the peripheral blood stream meets the neuronal 
environment.45 The barrier consists of brain endothelial cells which allow essential nutrients to 
pass through but blocks neurotoxic metabolites.45 Crossing the BBB is essential for any 
compound to be effective as a neuroprotective medicine.45 There are two parameters which 
determine the probability of a compound of crossing the BBB.45 The octanol/water partition (log 
P) is the first parameter. Log P is a measure of the lipophilicity of the compound.45 An optimal 
lipophilicity is needed for a compound to cross the BBB.45 
In our research, we have chosen one promising compound from the set of synthesized MB 
analogues and have reduced it to its salt form (Figure 2.5). The reduced salt was orally 
administered to mice to judge its ability to cross the BBB. 
 
Figure 2.5. The reduced salt form of the 16-carbon MB analogue.  
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2.2. Results 
Synthesis of MB and MV analogues 
In our efforts to modify the parent compounds MB and MV to decrease their cytotoxicity and 
increase NADH oxidation, a total of twenty-two different analogues were synthesized (Figures 
2.2 and 2.3). The syntheses of MB analogues (Figure 2.2) were carried out using a Wittig 
reaction as the key step. The syntheses of MV analogues (Figure 2.3) involved hydrolysis of an 
imine bond as the key step. The syntheses of the eleven MB analogues began with protection of 
the free -NH group of the commercially available 2-cyanophenothiazine. Extraction of the proton 
by NaH followed by protection of the free N atom by di-tert-butyl dicarbonate afforded 34 in 
72% yield. Reduction of the -CN group of 34 using DIBAL-H followed by hydrolysis afforded 
35 in 81% yield. Treatment of 35 with each of nine alkyltriphenylphosphonium bromides in the 
presence of 1 M NaHMDS afforded the corresponding alkyl derivatives (36-44) in quite variable 
yields. The catalytic hydrogenation of the unsaturated aliphatic side chains using palladium-on-
carbon as the heterogeneous catalyst afforded the saturated compounds (45-53) in high yields 
with the exception of 48. The final step of the syntheses was a combination of two reactions. 
First, the Boc protecting group was removed using eight equivalents of trifluoroacetic acid. 
Then, the unprotected intermediate was oxidized with iodine in dichloromethane solvent 
followed by subsequent dimethylamine additions, affording eight MB analogues (1-4, 22, 24, 26, 
28) in moderate yields (Scheme 2.1).41  
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Scheme 2.1. Synthetic routes employed for compounds 1, 2, 3, 4, 22, 24, 26 and 28. 
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Alternatively, intermediate 53 was treated with 5 equivalents of morpholine to provide the tris-
morpholino derivative 9 in 27% yield (Scheme 2.2).41 Similarly, intermediate 46 was treated 
with piperidine to afford compound 30 in 94% yield (Scheme 2.3).41 Lastly, intermediate 49 was 
treated with diethylamine to afford analogue 32 in 67% yield (Scheme 2.4).41  
 
Scheme 2.2. Synthetic route employed for compound 9.  
 
Scheme 2.3. Synthetic route employed for compound 30.  
 
Scheme 2.4. Synthetic route employed for compound 32.  
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The syntheses of the all 11 MV derivatives involved basic hydrolysis as the key step. All the MB 
analogues (1-4, 22, 24, 26, 28, 9, 30 and 32) were hydrolyzed using potassium hydroxide, 
affording the corresponding MV analogues (11-14, 23, 25, 27, 29, 18, 31 and 33) in low yields 
(Schemes 2.5 – 2.8).70  
 
Scheme 2.5. Synthetic routes employed for compounds 11, 12, 13, 14, 23, 25, 27 and 29. 
 
Scheme 2.6. Synthetic route employed for compound 18. 
 
Scheme 2.7. Synthetic route employed for compound 31. 
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Scheme 2.8. Synthetic route employed for compound 33. 
The synthesis of the reduced salt form of 22 began with the reduction of 22 using NaBH4 as the 
reducing agent in ethanol followed by acetylation of the ensuing -NH functionality using acetic 
anhydride, affording 54 in a low yield. The removal of the acetyl group was mediated using by 5 
N hydrochloric acid, affording the reduced salt form of 22 in 50% yield (Scheme 2.9).77 
 
Scheme 2.9. Synthetic route employed for preparing the reduced form of 22.    
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Figure 2.6. Structures of the MB and MV analogues tested. Compounds 5-8, 10, 15-17 and 19-
21 were synthesized by Dr. Sandipan Roy Chowdhury.78 
Cytotoxicity 
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Figure 2.7. MB and MB analogues were evaluated for cytotoxicity toward FRDA lymphocytes 
following incubation for 24 or 48 h in glucose-free media (galactose), which forced the cells to 
rely on mitochondria to produce their ATP. The experiment was done by Dr. Omar Khdour. 
Cytotoxicity was measured using the LIVE/DEAD Viability/Cytotoxicity Kit for mammalian 
cells. MB itself and compounds 1-3 showed significant cytotoxicity at 2.5 μM concentration after 
a 48-h incubation. Compound 4 showed considerable improvement in cell viability. Compounds 
5-9 were not cytotoxic under the tested conditions. MV itself and compounds 10-11 were 
somewhat cytotoxic at 2.5 μM concentration after a 48-h incubation. However, MV analogues 
12-21 were not cytotoxic under the tested conditions (Figure 2.7). 
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Figure 2.8. MB and MB analogues were evaluated for cytotoxicity toward FRDA lymphocytes 
following incubation for 24 or 48 h in glucose-free media (galactose), which forced the cells to 
rely on mitochondria to produce their ATP. The experiment was done by Dr. Omar Khdour.  
Cytotoxicity experiment was performed to check whether the synthesized compounds were toxic 
to the cells. After both 24 h and 48 h incubations, all the compounds including MB itself proved 
to be toxic at the higher concentration except compound 30 (Figure 2.8). 
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Figure 2.9. MV and MV analogues were evaluated for cytotoxicity toward FRDA lymphocytes 
following incubation for 24 or 48 h in glucose-free media (galactose), which forced the cells to 
rely on mitochondria to produce their ATP. The experiment was done by Dr. Omar Khdour.  
For the MV series of compounds, after a 24 h incubation period all compounds proved to be 
toxic at higher concentrations except compound 31. After a 48 h incubation period, MV itself 
and compounds 25, 27 and 29 were much more toxic at the higher concentration than compounds 
31 and 33 (Figure 2.9). 
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Mitochondrial membrane potential 
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Figure 2.10. Flow cytometric analysis shows the effect of MB analogues 1-9 and MV analogues 
10-21 on Δm in FRDA lymphocytes using the ratiometric fluorescent probe JC-1. The 
experiment was done by Dr. Omar Khdour.  
The analogues were tested for their effects on inner mitochondrial membrane potential (Δψm) in 
FRDA lymphocytes using the JC-1 probe. Compounds 1-3 depolarized mitochondrial membrane 
potential, especially at 5 μM concentration. Compound 4 behaved the same as MB itself. 
Compound 5 showed significant improvement and compounds 6-9 were compatible with 
maintenance of mitochondrial membrane potential even at higher concentrations. For the MV 
series, compound 11 was least able to maintain Δψm. Compounds 10, 12 and MV itself showed 
similar potency. Compounds 15-18 were the best in maintaining mitochondrial membrane 
potential (Figure 2.10). 
 
Figure 2.11. MB analogues preserve Δm in BSO-treated FRDA lymphocytes using the 
ratiometric fluorescent probe TMRM. The experiment was done by Dr. Omar Khdour.  
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The analogues (5 and 15) were tested for their effects on inner mitochondrial membrane potential 
(Δψm) in FRDA lymphocytes using the lipophilic cationic probe TMRM in the presence and 
absence of BSO. Both MB and MV itself were able to boost mitochondrial membrane potential 
in presence of BSO. Both compounds 5 and 15 showed further improvement in maintaining 
Δψm. However, compound 5 was slightly better than 15 at both 0.1 and 1 μM concentrations 
(Figure 2.11).  
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Figure 2.12. Effect of the new MBs on Δψm in FRDA lymphocytes using the ratiometric 
fluorescent probe JC-1. The experiment was done by Dr. Omar Khdour.  
The membrane potential assay was performed to test the ability of the synthesized compounds to 
maintain the inner mitochondrial membrane integrity. In the MB series, compounds 24, 26 and 
28 as well as MB itself could not maintain Δψm at higher concentrations. Compounds 30 and 32 
both also had a deleterious effect on Δψm at higher concentration albeit to a much lesser extent. 
The MV series of compounds follow a similar pattern to that of their MB counterparts. 
Compounds 31 and 33 were able to maintain Δψm at both the tested concentrations (Figure 2.12).  
NADH oxidase activity 
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Figure 2.13. Effect of MB analogues on mitochondrial NADH oxidase activity (complexes I, III 
and IV). The experiment was done by Dr. Omar Khdour.  
NADH oxidase activity, which is a measure of complex I-III and IV activity was determined in 
presence of the MB and MV analogues. MB itself was not inhibitory to any of the complexes. 
However, compounds 1-4, 7 and 9 were inhibitory, especially at higher concentrations. 
Compounds 5 and 6 were less inhibitory whereas compound 8 showed the least inhibition at all 
concentrations. Similarly, MV itself exhibited no inhibition. However, compounds 11, 12 and 20 
were inhibitory at higher concentration. Compounds 13 and 15 were the least inhibitory at all 
concentrations (Figure 2.13).  
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Reactive Oxygen Species 
 
Figure 2.14. Flow cytometric analysis of FRDA lymphocyte cells stained with 
dichlorodihydrofluorescein diacetate (DCFH-DA) for 20 min, following pretreatment with the 
test compounds for 16 h, and subsequent treatment with diethyl maleate (DEM) for 80 min to 
induce the production of ROS by depleting glutathione. The experiment was done by Dr. Omar 
Khdour.  
The ability of the synthesized compounds to suppress ROS was studied (Figure 2.14). In the MB 
series, compound 2 was able to suppress ROS the most at 2.5 μM concentration and compound 8 
was the best ROS quencher at 0.25 μM concentration. In the MV series, compound 20 and 21 
proved to be the most potent ROS quencher at both concentrations (Figure 2.14).  
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ATP assay 
 
 
Figure 2.15. Total ATP level in FRDA lymphocytes following incubation with test compounds 
for 24 h in glucose free media (25 mM galactose) to force the cell to use OXPHOS for energy 
40 
 
production. The results are expressed as percentage of total ATP relative to untreated control. 
The experiment was done by Dr. Omar Khdour.  
The measurement of ATP levels in the presence of the synthesized compounds has been 
performed to evaluate the compounds for their ability to support ATP production in the 
mitochondria. MB itself and compounds 1-3 were unable to augment ATP production, especially 
at higher concentration. Compounds 4, 5, 7 and 8 were able to increase ATP production relative 
to the untreated control. MV itself was detrimental to ATP production at higher concentrations. 
Better results were obtained for compounds 14, 20 and 21. Compounds 15-17 also increased 
ATP levels relative to the untreated control (Figure 2.15). 
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Figure 2.16. Total ATP level in FRDA lymphocytes following incubation with test compounds 
for 24 h in glucose free media (25 mM galactose) to force the cell to employ OXPHOS. Results 
are expressed as percentage of total ATP relative to untreated control. The experiment was done 
by Dr. Omar Khdour.  
The measurement of ATP levels after treatment of the FRDA cells with the synthesized 
compounds showed that in the MB series of compounds, only compounds 30 and 32 were able to 
support ATP production nearly equally at all concentrations. Similarly, in the MV series of 
compounds only 31 and 33 were able to support ATP production even at higher concentrations 
(Figure 2.16).  
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Cytoprotection 
 
 
Figure 2.17. Cytoprotective effects of methylene blue derivatives on cultured FRDA cells 
treated with 5 mM diethylmaleate (DEM) for 6 h to induce oxidative stress by depleting cells of 
glutathione. Flow cytometric determination of cell viability by fluorescence labeling was used 
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employing calcein acetoxymethyl-ester and ethidium homodimer-1 (EthD-1) as live and dead 
cell stains, respectively. Cell viability was expressed as the percentage of cells relative to control. 
The experiment was done by Dr. Omar Khdour.  
The cytoprotection assay was performed to assess the ability of the synthesized compounds to 
protect the cells from induced oxidative stress. In the presence of DEM, MB itself and 
compounds 1-2 were moderately potent in providing protection to cells. Compounds 3-5 were 
the best cytoprotective compounds, whereas compounds 6-9 were cytoprotective only at the 
highest concentration tested. In the MV series, compound 14 provided the most cytoprotection at 
all concentrations tested (Figure 2.17).    
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Figure 2.18. Cytoprotective effects of methylene blue derivatives in cultured FRDA cells treated 
with rotenone (1 µM) for 24 h to shut down OX-PHOS. The experiment was done by Dr. Omar 
Khdour.   
The cytoprotection assay was repeated using a different stressor rotenone, which is a complex I 
inhibitor and thus shuts down OX-PHOS. In the MB series, compounds 4, 5 and 8 produced the 
best results at all three concentrations tested indicating that they were able to act as an electron 
bypass carrier, bypassing complex I. The rest of the compounds, along with MB itself, were 
either ineffective in conferring cytoprotection or were only slightly protective (Figure 2.18). 
Microsomal stability assay 
Table 1. In vitro microsomal stability of some MB analogues following incubation with bovine 
liver microsomes for 30 min. The results are expressed as percent of compound recovered after 
treatment with activated microsomes. The experiment was done by Dr. Omar Khdour.  
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Compound Recovery 
(%) 
methylene blue 70  
compd 5  80 
compd 15 77  
compd 7 98  
methylene violet 73 
idebenone 64 
 
In vitro microsomal stability assay was performed to check the stability of the compounds in 
presence of the oxidative enzymes usually present in the liver. Table 1 shows that both 
compounds 5 and 7 were more stable than MB itself. Compound 15 was also more stable than 
parent compound MV itself, albeit only slightly. 
Frataxin assay 
 
Figure 2.19. Effect of MB/MV and analogues 24-33 on frataxin protein expression level in 
Friedreich ataxia cells GM15850. Frataxin levels were detected following 48 hours of treatment 
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using human frataxin in vitro SimpleStep ELISA kit (Abcam, Cambridge, UK) assay. Values are 
expressed in means ± SEM. The experiment was done by Dr. Lei Zheng.  
The ability to increase frataxin protein levels could be the key to cure Friedreich’s ataxia. 
Amongst the newly synthesized compounds, compound 24 in the MB series and compound 31 in 
the MV series, were both able to increase FXN levels at 250 nM concentration to greater extent 
than MB itself at the same concentration (Figure 2.19).  
 
Figure 2.20. Effect of MB analogues MB and its reduced salt form (MBH2), compound 22, and 
its reduced salt form (22H2) on frataxin protein expression level in GM15850 Friedreich’s ataxia 
cells. Frataxin levels were detected following 48 hours of treatment using human frataxin in vitro 
SimpleStep ELISA kit (Abcam, Cambridge, UK) assay. Values are expressed in means ± SEM. 
The experiment was done by Dr. Lei Zheng.  
The frataxin protein expression assay was performed with the oxidized and reduced forms of MB 
and compound 22. Figure 2.20 indicates that for both MB and its 16-carbon analogue, the 
reduced form enhanced FXN expression more than the oxidized form mainly because of the 
greater uptake of the reduced salt form by the cell. 
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Frataxin mRNA expression assay 
 
Figure 2.21. Effect of MB/MV and analogues on FXN mRNA expression. Data were 
represented as means ± SEM. The experiment was done by Dr. Lei Zheng.  
The measurement of the FXN mRNA levels supported the findings in Figure 2.20. Compound 24 
showed a much greater increase in FXN mRNA levels at 250 nM concentration than any other 
compound (Figure 2.21).  
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Mitochondrial biogenesis assay 
 
Figure 2.22. Effect of MB/MV analogues 24-33 on mitochondrial biogenesis in Friedreich ataxia 
cells GM15850 was evaluated using an ELISA kit (Abcam, Cambridge, UK) based on 
simultaneous detection of two mitochondrial proteins, SDH-A and COX-1. The ratio between 
these two proteins Cox-1/SDH-A reflects the intensity of mitobiogenesis. Values are expressed 
in means ± SEM. The experiment was done by Dr. Nishant P. Visavadiya. 
The mitobiogenesis experiment had taken into account the ability of the synthesized compounds 
to promote the formation of proteins in the mitochondria which originate from mitochondrial 
DNA, for example Cox-1. Again, compound 24 proved to be the most potent in promoting 
mitobiogenesis at 250 nM concentration (Figure 2.22).  
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Figure 2.23. Effect of MB analogues MB/MBH2 and 22/22H2 on mitochondrial biogenesis in 
Friedreich’s ataxia cells (GM15850) was evaluated using an ELISA kit (Abcam, Cambridge, 
UK) based on simultaneous detection of two mitochondrial proteins, SDH-A and COX-1. The 
ratio between these two proteins Cox-1/SDH-A reflects the extent of mitobiogenesis. Values are 
expressed in means ± SEM. The experiment was done by Dr. Nishant P. Visavadiya. 
The mitobiogenesis experiment was carried out using the oxidized and reduced forms of both 
MB itself and compound 22. At 250 nM concentration the reduced MB is more potent than its 
oxidized form in increasing mitobiogenesis. At 50 nM concentration reduced 22 is the more 
potent than its oxidized form in increasing mitobiogenesis (Figure 2.23). This observation 
indicates that although the oxidized and reduced forms of both MB and compound 22 are in 
equilibrium in cells, the reduced form has a greater uptake in the cell than the oxidized form 
which results in the reduced forms of both MB and compound 22 being more potent in 
increasing mitobiogenesis than their oxidized forms.   
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SOD2 mRNA expression assay     
 
Figure 2.24. Effect of MB/MV and analogues on SOD2 mRNA expressions. Data were 
represented as means ± SEM. The experiment was done by Dr. Lei Zheng. 
Superoxide dismutase is an important enzyme because it plays a major role in detoxifying the 
mitochondria. Amongst the synthesized compounds, 24 was the most potent at 250 nM 
concentration in promoting mRNA expressions for the synthesis of the SOD2 enzyme (Figure 
2.24).  
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Bioavailability assay 
Table 2. Bioavailability of the reduced salt formulation of MB, and compound 22 in perfused 
brain and blood following oral administration of 30 mg per kilogram in CD-1 mice. The 
experiment was done by Dr. Omar Khdour.  
Time point Perfused brain (nmoles/g of protein) Blood (nmoles/mL) 
1 h (MB-reduced salt) 0.33 ± 0.03 (330 ± 25 nM) 0.51 ± 0.1 (508 ± 96 nM) 
4 h 0.25 ± 0.01 (248 ± 11 nM) 0.22 ± 0.05 (220 ± 48 nM) 
   
1 h (22H2) Trace (below the HPLC detection limit)  0.06 ± 0.02 (61 ± 21 nM) 
4 h             0.08 ± 0.01 (74 ± 12 nM) 0.60 ± 0.2 (444 ± 170 nM) 
 
Crossing the BBB is essential for any compound to be of medicinal value for a 
neurodegenerative disorder. The ability of the reduced forms of both MB itself and compound 22 
to cross the BBB and enter the brain, was tested in a mouse model. Although, only traces of 
22H2 were found to have entered the brain after 1 h, there was a considerable improvement after 
4 h. Moreover, after 4 h 22H2 was found at a higher concentration in the blood compared to the 
reduced form of MB itself after the same amount of time. (Table 2).  
2.3. Discussion 
The starting molecule for the synthesis of all the MB and MV analogues was 2-
cyanophenothiazine. The initial protection step involving the use of Boc2O gave a high yield. 
The next reaction involving the use of DIBAL-H as the reducing agent followed by hydrolysis, 
also yielded good amounts of the desired product. The use of alkyltriphenylphosphonium 
bromides for the Wittig reaction step generally gave good yields. However, the reactions 
involving the use of heptyltriphenylphosphonium bromide and decyltriphenylphosphonium 
bromide had low yields. It was interesting to note that the Wittig reaction product at times 
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changed color from light yellow to grey. The reason for the color change could be the 
interconversion from the cis to the trans isomer. The hydrogenation step for the reduction of the 
double bond in the long aliphatic side chain involved palladium-on-carbon as the heterogenous 
catalyst. The reaction was performed in a hydrogenation apparatus. The hydrogenation reaction 
generally gave high yields. The final step leading to all the MB analogues involved a 
combination of two reactions. The deprotection of the Boc group produced an intermediate 
which was used directly for the next step without further purification. Subsequently, the 
secondary amine additions preceeded by oxidation of the phenothiazine core by the use of iodine 
as the oxidant. The yields for the final step ranged from moderate to good. Variations in the 
secondary amines used included acyclic (e.g., dimethyl and diethyl) and cyclic amines (e.g., 
piperidine and morpholine). 
Hydrolysis of the imine bond of all the MB analogues afforded the corresponding MV 
derivatives in low yields. All the hydrolysis reactions were carried out at room temperature 
except for the synthesis of compound 11, which required an elevated temperature (70 oC) for the 
hydrolysis to occur. It is worth mentioning that all the MV analogues were considerably less 
polar than their MB counterparts, mainly because of the absence of a positive charge.  
The reduction of compound 22 was achieved by using sodium borohydride as the reductant. 
Once reduced, the product had to be kept under an inert atmosphere of argon because of its 
propensity to oxidize quickly in the presence of atmospheric oxygen.77 Moreover, the reduced 
product was not stored overnight. Instead it was immediately converted to the acetylated form, 
which was not oxygen sensitive and therefore could be stored for long periods of time.77 The 
final reduced salt form of 22 was also oxygen sensitive and special care had to be taken for its 
storage. The compound, after being dried in a lyophilizer, was flushed thoroughly with argon 
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followed by storage in a desiccator. The desiccator was also flushed well with an inert gas before 
being stored in the freezer at _20 oC.  
MB has been reported to be cytotoxic at high concentrations (>100 nM) because of its auto-
oxidizing ability.79 Due to auto-oxidation, MB itself augments radical formation and thereby 
becomes toxic to the cells. This auto-oxidation phenomenon of MB is the reason behind its 
hormetic dose response.79 It was, therefore, important to check whether the synthesized MB and 
MV analogues were cytotoxic to cultured FRDA lymphocytes. The cells were grown on a 
galactose medium. Cells grown on glucose-free media rely wholly on mitochondrial OX-PHOS 
for their ATP production. Therefore, such cells are more vulnerable to mitochondrial toxins.41 
Experimental evidence involving the synthesized MB analogues (1-9) suggested that cytotoxicity 
decreased with increased lipophilicity (Figure 2.7). Moreover, the same experiment involving 
MB analogues (24, 26, 28, 30 and 32) suggested that an optimized lipophilicity involving cyclic 
amines and a shorter side chain was also effective in making a compound less cytotoxic (Figure 
2.8). Similarly, for MV analogues (10-21), the results suggested that cytotoxicity decreases with 
increased lipophilicity (Figure 2.7). Again, for MV compounds (25, 27, 29, 31 and 33) it can be 
concluded that compounds with an optimized lipophilicity involving a shorter side chain but 
bulkier amines were less cytotoxic to FRDA cells (Figure 2.9). For a better understanding of the 
above discussion, the structures of the best compounds (least cytotoxic) are shown in Figure 2.25 
below. 
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Figure 2.25. The structures of the least toxic compounds in the cytotoxicity assay. 
The JC-1 probe was used to test the effect of the MB and MV analogues on Δψm. JC-1 is a dual 
emission potential sensitive fluorescent dye that selectively accumulates inside mitochondria 
which have proper membrane polarity (positive outside, negative inside).1,41 In the cytosol, JC-1 
exists as monomers emitting green fluorescence whereas when inside a properly polarized 
mitochondria it aggregates and emits red fluorescence.41 FACS analysis enabled the 
determination of red (J-aggregate)/green (J-monomer ratio), which in turn gave us a clear picture 
of the physiological state of the mitochondria.41 The experimental results involving MB 
analogues (1-9, 24, 26, 28, 30 and 32) suggested that compounds with bulkier amines (6-9, 30 
and 32) were able to preserve Δψm better than the other analogues (Figures 2.10 and 2.12). A 
similar pattern was observed with MV analogues (10-21, 25, 27, 29, 31 and 33). Compounds 
with longer side chains (15) and bulkier amines (16-18, 31 and 33) proved to be better at 
maintaining mitochondrial membrane polarity than the other analogues (Figures 2.10 and 2.12). 
FCCP, an uncoupler of oxidative phosphorylation which depolarizes the inner membrane was 
used as a negative control. In a similar assay for testing the effect of compounds 5 and 15 on 
Δψm, the lipophilic cation TMRM was used. Mitochondria with intact membrane polarity impart 
55 
 
TMRM to a greater extent than depolarized mitochondria.70 The intensity of the red fluorescence 
of TMRM was used to determine the physiological state of the inner mitochondrial membrane.70 
The results from that assay showed that a seventeen-carbon side chain (compounds 5 and 15) 
was slightly better than their parent compounds in maintaining Δψm (Figure 2.11). BSO, an 
enzyme inhibitor of glutathione biosynthesis was used as the negative control. The structures of 
the best compounds in maintaining membrane polarity has been shown in Figure 2.26. 
       
Figure 2.26. The structures of the best compounds in the membrane polarity assay.     
An NADH oxidase activity assay was performed to check whether any of the synthesized 
compounds were inhibitory to complexes I, III and IV. According to the results obtained (Figure 
2.13), the di-morpholino derivative of MB (compound 8) in the MB series of compounds, having 
a 17-carbon side chain proved to have the least inhibition of the enzyme complexes. In the MV 
series, compounds 13 and 15 proved to have the least inhibition of the mitochondrial complexes 
I, III and IV (Figure 2.13). It must be noted that both MB and MV themselves did not have any 
inhibitory effects on those complexes presumably because they did not bind to any of the 
complexes. The best compounds (least inhibitory) towards NADH oxidase has been shown in 
Figure 2.27. 
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Figure 2.27. The best compounds for the NADH oxidase assay.  
The ability of the synthesized compounds to suppress ROS was tested by monitoring the ROS-
induced formation of the highly fluorescent product DCF from the non-fluorescent dye DCFH-
DA in cultured FRDA lymphocytes (Figure 2.14). The results suggested that the 11-carbon MB 
analogue (compound 2) and the di-morpholino MB analogue (compound 8) were both potent 
ROS quenchers at two different concentrations tested. In the MV series, the analogues 
possessing a long aliphatic side chain on the exocyclic amine (compounds 20 and 21) proved to 
be the most potent ROS quenchers. The structures of the best compounds (most potent ROS 
quenchers) are shown in Figure 2.28. 
  
Figure 2.28. The structures of the most potent ROS quenchers. 
Mitochondria are responsible for producing 90% of our ATP by OXPHOS.7,8 Dysfunctional 
mitochondria will be unable to produce sufficient amounts of ATP for cells to survive. 
Moreover, it is known that MB does not support the pumping of protons into the intermembrane 
space in sync with the alternate electron flow pathway.41 Therefore, it is expected that using MB 
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as a method of rescuing electron transport in the mitochondria might well hamper ATP 
production. Accordingly, the synthesized MB and MV compounds were tested to check their 
ability to augment ATP levels. The results indicated that compounds with increased lipophilicity 
resulting either from a longer side chain (compounds 5 and 15), bulkier exocyclic amines 
(compounds 30-33) or both (compounds 6-9 and 16-18) were able to support ATP production to 
the greatest extent (Figure 2.15 and 2.16). Although, the electron bypassing by MB and MV 
analogues do not support proton pumping at complexes I and III (there is still proton pumping at 
complex IV), the selected compounds mentioned had been able to promote ATP production most 
likely because the efficiency (greater turnover) of the electron shuttling process between NADH 
and complex IV by these analogues were sufficient enough to promote proton pumping at 
complex IV so as to make up for the loss of proton pumping by complexes I and III. The 
structures of the key compounds for ATP production has been shown in Figure 2.29. 
 
 
Figure 2.29. The structures of key compounds for ATP production. 
Cells treated with DEM get depleted of its natural antioxidant glutathione thereby becoming 
susceptible to oxidative damage.41 The results showed that MB analogues having 13-carbon, 15-
carbon and 17-carbon side chains (compounds 3-5) were the most cytoprotective whereas the 
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analogues with the bulky amines (compounds 7-9) were cytoprotective only at higher 
concentrations. For the MV series, compound 14 having a 15-carbon side chain proved to be 
very cytoprotective (Figure 2.17). In a different experiment, the cells were treated with the 
complex I inhibitor rotenone to block ETC function. MB analogues having 15-carbon and 17-
carbon side chains (compounds 4 and 5) and the di-morpholino MB derivative (compound 8) 
proved to be cytoprotective (Figure 2.18). The structures of the key cytoprotective compounds 
are shown in Figure 2.30. 
 
Figure 2.30. The structures of key cytoprotective compounds. 
Augmenting frataxin protein expression is a potential key to curing FRDA.44 Accordingly, we 
have tested some chosen MB and MV compounds for their ability to promote FXN levels. In an 
experiment involving the ELISA technique (Figure 2.19 and 2.20) it was discovered that MB 
analogue 24 (having a 10-carbon side chain) and MV analogue 31 (having a bulky cyclic amine) 
helped promote FXN synthesis. It was also discovered that the reduced forms of both MB itself 
and its analogue 22 (having a 16-carbon side chain) were better at increasing FXN than their 
corresponding oxidized forms. Now, although the exact mechanisms by which these compounds 
increase FXN is still unclear, we have proposed three ways in which it happens. First, these 
compounds can support the biosynthesis of FXN mRNA at the transcriptional level.41 Second, at 
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the post-transcriptional level, these compounds might be involved in resisting FXN 
degradation.41 Third, the nuclear factor erythroid-derived 2 (Nrf2) has been shown previously to 
be linked to FXN expression.41 In addition, MB has been reported to activate the Nrf2 
pathway.72,81 Therefore, there is reason to believe that MB and its analogues, by virtue of Nrf2 
pathway activation, can promote FXN expression. Finally, the greater potency of the reduced 
form in augmenting FXN levels is mainly due to the greater facility by which the reduced form 
can cross the cell membrane as compared to the oxidized form (Table 2).68 The structures of key 
compounds that increase FXN are shown in Figure 2.31. 
 
Figure 2.31. The key compounds which increased FXN. 
In order to determine a possible role of the MB analogues in augmenting the biosynthesis of 
FXN mRNA at the transcriptional level, we performed an experiment designed to measure the 
quantities of FXN mRNA in the presence of our synthesized compounds. The results showed 
that the 10-carbon MB analogue (compound 24) increased FXN mRNA levels more than the 
other analogues tested. Although the FXN mRNA level in the presence of compound 24 was not 
significant enough to match those of the healthy cells, they were certainly more than those of the 
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FRDA cells (Figure 2.21). This could mean that compound 24 is acting at the transcriptional or 
translational level. The structure of compound 24 has been shown in Figure 2.31. 
Previous reports have shown that there is a positive correlation between FXN protein expression 
and mitochondrial biogenesis.82 Moreover, PGC1α (a mitobiogenesis master regulator) has been 
reported to positively regulate FXN gene expression.83 Again, MB is known for its electron 
shuttling capabilities which leads to sirtuin activation, deacetylation and proper functioning of 
PGC1α.72-76 Therefore, it can be rationalized that the synthesized MB and MV compounds 
should have a positive effect on mitobiogenesis. The experimental results (Figures 2.22 and 2.23) 
revealed that the 10-carbon MB analogue (compound 24) which had shown promising results in 
earlier FXN expression assays, also was best in supporting mitobiogenesis. In addition, the 
reduced forms of both MB itself (MBH2) and compound 22 (22H2) proved to be better than their 
oxidized forms, as was the case in the earlier FXN expression assays. Nonetheless, more 
experiments still need to be conducted to determine whether the salutary effects of these 
synthesized compounds are due to its antioxidant properties or because of its electron shuttling 
capabilities. The latter seems more likely. The structures of the compounds which promote 
mitobiogenesis are shown in Figure 2.32.  
 
Figure 2.32. The structures of the compounds which promote mitobiogenesis.  
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Superoxide dismutase is an important enzyme instrumental in the ROS detoxification process 
inside the mitochondria.12-16 Therefore, we decided to check whether any of our synthesized 
compounds were enabling the biosynthesis of this antioxidant enzyme at the mRNA or 
transcriptional level. We found that the 10-carbon MB analogue (compound 24) was the best 
compound (Figure 2.24). Sirtuin activation by MB, followed by the deacetylation and 
phosphorylation of PGC1α and subsequent promotion of mitobiogenesis is a known 
phenomenon.72-76 Although yet to be confirmed conclusively, it is possible that compound 24 is 
working both as an efficient electron bypass carrier and in helping the SOD mRNA expression. 
The structure of compound 24 is shown in Figure 2.32. 
For the purpose of therapeutic intervention via oral administration, compounds need to be stable 
in the presence of the oxidative enzymes of the liver. Accordingly, we decided testing some of 
our compounds for their metabolic stability. The results (Table 1) showed that the two 
synthesized MB analogues, one with a 17-carbon side chain and dimethyl amine exocyclic 
groups and the other with cyclic amine groups (compound 5 and 7) were tested. Both showed up 
to be metabolically more stable than their parent compounds. The structures of compounds 5 and 
7 are shown in Figure 2.35 below. 
 
Figure 2.33. The metabolically stable compounds 5 and 7. 
The BBB separates the circulating blood in the periphery from the neuronal environment by 
forming a semipermeable barrier which allows the passive diffusion of water, some gases and 
lipid soluble small molecules but prevents the entry of other large hydrophilic molecules and 
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bacteria. It is important for any compound of medicinal value in the central nervous system to be 
able to cross the BBB.45 Accordingly, an experiment was carried out using mouse models to 
check whether our synthesized compound (22H2) was able to cross the BBB and get to the brain. 
The results showed that the reduced form of compound 22 was able to cross the BBB but only 
after 4 h (Table 2). The structures of 22 and 22H2 are shown below in Figure 2.34 for reference. 
 
Figure 2.34. The structures of compounds 22 and its reduced salt form 22H2. 
All in all, compound 24 possessing a side chain length of 10-carbon atoms seems to be the most 
promising compound in terms of increasing FXN levels, mitobiogenesis and mRNA levels of 
mitochondrial proteins. In addition, the reduced form of the synthesized compound 22H2 is 
seemingly more potent than its oxidized form in increasing FXN, mitobiogenesis and crossing 
the BBB. Finally, in general, the compounds having a side chain length of 15-17 carbon atoms or 
those possessing cyclic amine substituents seemed more promising than others in assays such as 
cytotoxicity, maintaining membrane potential, augmenting ATP, supporting NADH oxidase and 
complex I activities and in maintaining metabolic stability.    
2.4. Experimental section 
Reagent grade chemicals and solvents were purchased from Sigma-Aldrich Chemicals and were 
used without further purification. All the reactions were performed under an argon atmosphere, 
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unless otherwise specified. Thin layer chromatography (TLC) plates (precoated glass plates with 
silica gel 60 F254, 0.25 mm thickness) were used for analytical TLC and were visualized by UV 
irradiation (254 nm). Flash chromatography was carried out using Silicycle 200−400 mesh silica 
gel. 1H and 13C NMR spectra were obtained using a Varian 500 MHz NMR spectrometer. 
Chemical shifts (δ) are reported in parts per million (ppm) and are referenced to residual CHCl3 
(δ 7.26 ppm for 1H NMR and δ 77.16 for 13C NMR) as the internal standard. Splitting patterns 
are designated as s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet. 
High resolution mass spectra were obtained at the Arizona State University CLAS High 
Resolution Mass Spectrometry Facility. 
 
tert-Butyl 2-Cyano-10H-phenothiazine-10-carboxylate (34). A sample of 2.00 g (8.90 mmol) 
of 2-cyanophenothiazine was dissolved in 25 mL of anhydrous DMF. The reaction mixture was 
cooled to 0 oC and 0.53 g (13.3 mmol) of 60% NaH was added. The dark mixture was stirred at 0 
oC for an additional 15 min and 2.33 g (10.6 mmol) of di-tert-butyl dicarbonate was added. The 
reaction mixture was stirred at room temperature for 18 h and was then diluted with 60 mL of 
brine. The aqueous layer was extracted with three 25-mL portions of ethyl acetate. The combined 
organic extract was dried over anhydrous MgSO4 and concentrated under diminished pressure. 
The crude was purified on a silica gel column (20 × 3 cm). Elution with 9:1 hexanes-ethyl 
acetate gave 34 as a pale yellow solid: yield 2.10 g (72%); silica gel TLC Rf 0.26 (9:1 hexanes-
ethyl acetate); 1H NMR (CDCl3)   (s, 9H), 7.16-7.20 (m, 1H), 7.28-7.33 (m, 2H), 7.40 (s, 
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2H), 7.49 (d, 1H, J = 8.4 Hz) and 7.80 (s, 1H); 13C NMR  28.1, 83.1, 110.2, 118.2, 126.6, 127.2, 
127.3, 127.5, 128.1,129.1, 130.3, 130.6, 137.7, 139.0, 139.1 and 151.8; mass spectrum (APCI), 
m/z 325.1017 (M+H)+  (C18H17N2O2S requires 325.1011). 
 
tert-Butyl 2-Formyl-10H-phenothiazine-10-carboxylate (35). To a solution of 2.30 g (7.10 
mmol) of 34 in 25 mL of anhydrous CH2Cl2 was added dropwise at 
_78 oC, 8.50 mL (6.78 g, 8.50 
mmol) of 1 M DIBAL-H in toluene. The reaction mixture was stirred at _78 oC for 3 h and was 
then diluted with 30 mL of brine. The aqueous layer was extracted with three 30-mL portions of 
CH2Cl2. The combined organic extract was dried over anhydrous MgSO4 and was concentrated 
under diminished pressure. The residue was purified on a silica gel column (20 × 3 cm). Elution 
with 9:1 hexane-ethyl acetate afforded 35 as a yellow solid: yield 1.88 g (81%); silica gel TLC Rf 
0.17 (9:1 hexane-ethyl acetate); 1H NMR (CDCl3)   (s, 9H), 7.14-7.18 (m, 1H), 7.26-7.32 
(m, 2H), 7.44 (d, 1H, J = 8.0 Hz), 7.52 (d, 1H, J = 7.4 Hz), 7.64 (d, 1H, J = 8.0 Hz), 7.99 (s, 1H) 
and 9.96 (s, 1H); 13C NMR  28.2, 82.9, 126.5, 126.7, 127.2, 127.3, 127.5, 127.9, 128.4, 130.6, 
135.1, 138.0, 139.2, 140.3, 152.1 and 190.9; mass spectrum (ESI), m/z 328.1003 (M+H)+  
(C18H18NO3S requires 328.1007).  
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tert-Butyl (E)-2-(Pent-1-enyl)-10H-phenothiazine-10-carboxylate (36). A sample containing 
2.30 g (5.81 mmol) of (1-butyl)triphenylphosphonium bromide was dissolved in 25 mL of 
anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated dropwise with 
5.81 mL (5.22 g, 5.81 mmol) of sodium bis(trimethylsilyl) amide and the resulting solution was 
stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated with 1.90 g 
(5.81 mmol) of 35 and dissolved in 15 mL of anhydrous tetrahydrofuran. The reaction mixture 
was stirred at 0 oC for 18 h. The product was extracted with two 30-mL portions of 
dichloromethane. The organic phase was washed with 20 mL of brine, dried over anhydrous 
Na2SO4 and concentrated under diminished pressure. The residue was purified on a silica gel 
column (20 × 3 cm). Elution with 4:1 hexane-dichloromethane afforded 36 as a yellow solid: 
yield 1.3 g (62%); silica gel TLC Rf  0.66 (9:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 
1.03 (t, 3H, J = 7.2 Hz), 1.57 (s, 11H), 2.42 (q, 2H, J = 7 Hz), 5.75 (m, 1H), 6.48 (d, 1H, J = 2 
Hz), 7.15 (m, 2H), 7.32 (m, 3H), 7.58 (s, 1H) and 7.63 (d, 1H, J = 8 Hz); 13C NMR (CDCl3) δ 
13.6, 22.8, 27.8, 30.3, 81.5, 125.7, 126.1, 126.3, 126.7, 127.0, 127.2, 127.7, 127.8, 129.7, 131.8, 
133.2, 136.2, 138.2, 138.5 and 152.0; mass spectrum (APCI), m/z 368.1680 (M+H)+ 
(C22H26NO2S requires 368.1684). 
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tert-Butyl (E)-2-(Oct-1-enyl)-10H-phenothiazine-10-carboxylate (37). A sample containing 
6.30 g (14.4 mmol) of (1-heptyl)triphenylphosphonium bromide was dissolved in 45 mL of 
anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated dropwise with 
14.4 mL (12.9 g, 14.4 mmol) of sodium bis(trimethylsilyl) amide and the resulting solution was 
stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated with 4.70 g 
(14.4 mmol) of 35, dissolved in 25 mL of anhydrous tetrahydrofuran. The reaction mixture was 
stirred at 0 oC for 18 h. The product was extracted with two 50-mL portions of dichloromethane. 
The organic phase was washed with 40 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 3 
cm). Elution with 3:2 hexane-dichloromethane afforded 37 as a yellow solid: yield 0.90 g (15%); 
silica gel TLC Rf  0.50 (3:2 hexane-dichloromethane); 
1H NMR (CDCl3) δ 0.96 (s, 3H), 1.36 (s, 
6H), 1.55 (s, 10H), 2.25 (d, 1H, J = 5 Hz), 2.41 (d, 2H, J = 5 Hz), 5.73 (m, 1H), 6.42 (d, 1H, J = 
15 Hz), 7.12 (m, 2H), 7.31 (m, 3H), 7.55 (s, 1H) and 7.59 (d, 1H, J = 10 Hz); 13C NMR (CDCl3) 
δ 13.9, 22.4, 27.9, 28.5, 28.8, 29.7, 31.5, 81.6, 125.8, 126.2, 126.3, 126.7, 127.0, 127.1, 127.2, 
127.6, 129.8, 132.0, 133.5, 136.4, 138.3, 138.6 and 152.1; mass spectrum (APCI), m/z 410.2169 
(M+H)+ (C25H31NO2S requires 410.2148). 
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tert-Butyl (E)-2-(Non-1-enyl)-10H-phenothiazine-10-carboxylate (38). A sample containing 
2.40 g (5.20 mmol) of (1-octyl)triphenylphosphonium bromide was dissolved in 20 mL of 
anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated dropwise with 
5.20 mL (4.68 g, 5.20 mmol) of sodium bis(trimethylsilyl) amide and the resulting solution was 
stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated with 1.70 g 
(5.20 mmol) of 35, dissolved in 8 mL of anhydrous tetrahydrofuran. The reaction mixture was 
stirred at 0 oC for 18 h. The product was extracted with two 30-mL portions of dichloromethane. 
The organic phase was washed with 20 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 3 
cm). Elution with 4:1 hexane-dichloromethane afforded 38 as a colorless oil: yield 1.10 g (43%); 
silica gel TLC Rf  0.70 (1:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 0.96 (t, 3H, J = 7.5 
Hz), 1.38 (m, 8H), 1.53 (m, 2H), 1.56 (s, 9H), 2.42 (q, 2H, J = 6.6 Hz), 5.74 (m, 1H), 6.43 (t, 
1H, J = 10 Hz), 7.15 (m, 2H), 7.30 (m, 2H), 7.37 (d, 1H, J = 10 Hz), 7.55 (s, 1H) and 7.60 (d, 
1H, J = 5 Hz); 13C NMR (CDCl3) δ 14.0, 22.5, 28.0, 28.5, 29.1, 29.2, 29.8, 31.7, 81.7, 125.8, 
126.3, 126.4, 126.8, 127.1, 127.2, 127.3, 127.7, 129.8, 132.0, 133.7, 136.5, 138.4, 138.6 and 
152.3; mass spectrum (APCI), m/z 424.2330 (M+H)+ (C26H33NO2S requires 424.2305). 
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tert-Butyl (E)-2-(Dec-1-enyl)-10H-phenothiazine-10-carboxylate (39). A sample containing 
1.33 g (2.84 mmol) of (1-nonyl)triphenylphosphonium bromide was dissolved in 10 mL of 
anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated dropwise with 
2.84 mL (2.55 g, 2.84 mmol) of sodium bis(trimethylsilyl) amide and the resulting solution was 
stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated with 0.93 g 
(2.84 mmol) of 35, dissolved in 4 mL of anhydrous tetrahydrofuran. The reaction mixture was 
stirred at 0 oC for 18 h. The product was extracted with two 30-mL portions of dichloromethane. 
The organic phase was washed with 20 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 3 
cm). Elution with 4:1 hexane-dichloromethane afforded 39 as a colorless oil: yield 2.43 g (98%); 
silica gel TLC Rf  0.80 (1:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 0.96 (t, 3H, J = 5 Hz), 
1.35 (s, 10H), 1.53 (t, 2H, J = 10 Hz), 1.56 (s, 9H), 2.41 (q, 2H, J = 6.6 Hz), 5.74 (m, 1H), 6.43 
(d, 1H, J = 15 Hz), 7.15 (m, 2H), 7.30 (m, 2H), 7.37 (d, 1H, J = 10 Hz), 7.54 (1H, s) and 7.60 (d, 
1H, J = 10 Hz); 13C NMR (CDCl3) δ 14.1, 22.6, 28.1, 28.6, 29.2, 29.3, 29.4, 29.9, 31.8, 81.8, 
125.9, 126.3, 126.5, 126.8, 127.2, 127.3, 127.4, 127.7, 129.9, 132.1, 133.7, 136.5, 138.4, 138.7 
and 152.3; mass spectrum (APCI), m/z 438.2514 (M+H)+ (C27H35NO2S requires 438.2461). 
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tert-Butyl (E)-2-(Undec-1-enyl)-10H-phenothiazine-10-carboxylate (40). A sample containing 
0.79 g (1.64 mmol) of (1-decyl)triphenylphosphonium bromide was dissolved in 12 mL of 
anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated dropwise with 
1.64 mL (1.47 g, 1.64 mmol) of sodium bis(trimethylsilyl) amide and the resulting solution was 
stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated with 0.53 g 
(1.64 mmol) of 35, dissolved in 8 mL of anhydrous tetrahydrofuran. The reaction mixture was 
stirred at 0 oC for 18 h. The product was extracted with two 30-mL portions of dichloromethane. 
The organic phase was washed with 20 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 3 
cm). Elution with 4:1 hexane-dichloromethane afforded 40 as a yellow oil: yield 0.14 g (20%); 
silica gel TLC Rf  0.68 (1:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 0.93 (t, 3H, J = 
6.4Hz), 1.31 (s, 13H), 1.53 (s, 10H), 2.38 (q, 2H, J = 7Hz), 5.71 (m, 1H), 6.40 (d, 1H, J = 
11.2Hz), 7.13 (m, 2H), 7.28 (q, 2H, J = 7.4Hz), 7.35 (d, 1H, J = 7.6Hz), 7.49 (s, 1H) and 7.57 (d, 
1H, J = 7.6Hz); 13C NMR (CDCl3) δ 14.2, 22.8, 27.3, 28.3, 29.4, 29.7, 29.8, 29.9, 30.0, 32.0, 
82.1, 126.1, 126.6, 127.3, 127.5, 127.8, 127.9, 129.9, 130.0, 130.1, 132.3, 134.0, 136.7, 138.6, 
138.9 and 152.5; mass spectrum (APCI), m/z 452.2617 (M+H)+ (C28H38NO2S requires 
452.2623).  
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tert-Butyl (E)-2-(Tridec-1-enyl)-10H-phenothiazine-10-carboxylate (41). A sample 
containing 2.65 g (5.19 mmol) of (1-dodecyl)triphenylphosphonium bromide was dissolved in 25 
mL of anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated 
dropwise with 5.19 mL (4.67 g, 5.19 mmol) of sodium bis(trimethylsilyl) amide and the resulting 
solution was stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated 
with 1.70 g (5.19 mmol) of 35, dissolved in 15 mL of anhydrous tetrahydrofuran. The reaction 
mixture was stirred at 0 oC for 18 h. The product was extracted with two 50-mL portions of 
dichloromethane. The organic phase was washed with 40 mL of brine, dried over anhydrous 
Na2SO4 and concentrated under diminished pressure. The residue was purified on a silica gel 
column (20 × 3 cm). Elution with 4:1 hexane-dichloromethane afforded 41 as a yellow oil: yield 
1.60 g (64%); silica gel TLC Rf  0.68 (1:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 1.01 (t, 
3H, J = 7 Hz), 1.38 (s, 17H), 1.58 (s, 10H), 2.45 (q, 2H, J = 6.83 Hz), 5.76 (m, 1H), 6.45 (t, 1H, 
J = 10 Hz), 7.14 (m, 2H), 7.31 (m, 3H) and 7.62 (q, 2H, J = 10.3 Hz); 13C NMR (CDCl3) δ 13.9, 
22.5, 27.9, 28.4, 29.1, 29.2, 29.3, 29.5, 29.7, 31.7, 81.4, 125.7, 126.1, 126.2, 126.6, 127.0, 127.1, 
127.2, 127.6, 129.7, 131.9, 133.4, 136.2, 138.3, 138.5 and 152.0; mass spectrum (APCI), m/z 
480.2942 (M+H)+ (C30H42NO2S requires 480.2936).  
71 
 
 
tert-Butyl (E)-2-(Pentadec-1-enyl)-10H-phenothiazine-10-carboxylate (42). A sample 
containing 2.80 g (5.19 mmol) of (1-tetradecyl)triphenylphosphonium bromide was dissolved in 
25 mL of anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated 
dropwise with 5.19 mL (4.67 g, 5.19 mmol) of sodium bis(trimethylsilyl) amide and the resulting 
solution was stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated 
with 1.70 g (5.19 mmol) of 35, dissolved in 15 mL of anhydrous tetrahydrofuran. The reaction 
mixture was stirred at 0 oC for 18 h. The product was extracted with two 50-mL portions of 
dichloromethane. The organic phase was washed with 40 mL of brine, dried over anhydrous 
Na2SO4 and concentrated under diminished pressure. The residue was purified on a silica gel 
column (20 × 3 cm). Elution with 4:1 hexane-dichloromethane afforded 42 as a yellow oil: yield 
2.00 g (76%); silica gel TLC Rf  0.68 (1:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 0.98 (t, 
3H, J = 5 Hz), 1.36 (s, 22H), 1.56 (s, 9H), 2.42 (d, 2H, J = 5 Hz), 5.74 (m, 1H), 5.44 (d, 1H, J = 
10 Hz), 5.15 (m, 2H), 7.30 (m, 2H), 7.37 (d, 1H, J = 10 Hz), 7.55 (s, 1H) and 7.60 (d, 1H, J = 5 
Hz); 13C NMR (CDCl3) δ 14.1 22.6, 28.1, 28.6, 29.34, 29.38, 29.5, 29.6, 29.7, 29.9, 31.9, 81.7, 
125.9, 126.3, 126.4, 126.81, 126.86, 127.2, 127.3, 127.8, 129.9, 132.1, 133.6, 136.5, 138.4, 138.7 
and 152.3; mass spectrum (APCI), m/z 508.3258 (M+H)+ (C32H46NO2S requires 508.3249). 
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tert-Butyl (E)-2-(Hexadec-1-enyl)-10H-phenothiazine-10-carboxylate (43). A sample 
containing 1.82 g (3.30 mmol) of (1-pentadecyl)triphenylphosphonium bromide was dissolved in 
20 mL of anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated 
dropwise with 3.30 mL (2.97 g, 3.30 mmol) of sodium bis(trimethylsilyl) amide and the resulting 
solution was stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated 
with 1.08 g (3.30 mmol) of 35, dissolved in 15 mL of anhydrous tetrahydrofuran. The reaction 
mixture was stirred at 0 oC for 18 h. The product was extracted with two 30-mL portions of 
dichloromethane. The organic phase was washed with 20 mL of brine, dried over anhydrous 
Na2SO4 and concentrated under diminished pressure. The residue was purified on a silica gel 
column (20 × 3 cm). Elution with 5:1 hexane-dichloromethane afforded 43 as a colorless oil: 
yield 1.27 g (74%); silica gel TLC Rf  0.68 (1:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 
0.97 (t, 3H, J = 5 Hz), 1.35 (s, 22 H), 1.53 (m, 11H), 2.41 (q, 2H, J = 8.3 Hz), 5.74 (m, 1H), 6.42 
(t, 1H, J = 10 Hz), 7.15 (m, 2H), 7.30 (m, 2H), 7.38 (d, 1H, J = 5 Hz), 7.53 (s, 1H) and 7.60 (d, 
1H, J = 10 Hz); 13C NMR (CDCl3) δ 14.1, 22.7, 28.1, 28.6, 29.3, 29.4, 29.5, 29.6, 29.71, 29.74, 
29.9, 31.9, 81.8, 125.9, 126.4, 126.5, 126.8, 127.2, 127.3, 127.4, 127.7, 129.9, 132.1, 133.7, 
136.5, 138.5, 138.7 and 152.3; mass spectrum (APCI), m/z 522.3400 (M+H)+ (C33H48NO2S 
requires 522.3406). 
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tert-Butyl (E)-2-(Heptadec-1-enyl)-10H-phenothiazine-10-carboxylate (44). A sample 
containing 0.17 g (0.30 mmol) of (1-hexadecyl)triphenylphosphonium bromide was dissolved in 
10 mL of anhydrous tetrahydrofuran. The reaction mixture maintained at _78 oC was treated 
dropwise with 0.30 mL (0.27 g, 0.30 mmol) of sodium bis(trimethylsilyl) amide and the resulting 
solution was stirred at 0 oC for 3 h. The reaction mixture was cooled to _78 oC and then treated 
with 0.10 g (0.30 mmol) of 35, dissolved in 7 mL of anhydrous tetrahydrofuran. The reaction 
mixture was stirred at 0 oC for 18 h. The product was extracted with two 15-mL portions of 
dichloromethane. The organic phase was washed with 10 mL of brine, dried over anhydrous 
Na2SO4 and concentrated under diminished pressure. The residue was purified on a silica gel 
column (20 × 1 cm). Elution with 4:1 hexane-dichloromethane afforded 44 as a yellow oil: yield 
0.11 g (72%); silica gel TLC Rf  0.27 (9:1 hexane-dichloromethane); 
1H NMR (CDCl3) δ 0.93 (t, 
3H, J = 6.6 Hz), 1.31 (s, 26H), 1.52 (s, 9H), 2.38 (q, 2H, J = 6.9 Hz), 5.70 (m, 1H), 6.40 (d, 1H, 
J = 11.6 Hz), 7.11 (m, 2H), 7.26 (m, 2H), 7.33 (d, 1H, J = 7.6 Hz), 7.50 (s, 1H) and 7.56 (d, 1H, 
J = 8 Hz); 13C NMR (CDCl3) δ 14.2, 22.8, 28.2, 28.7, 29.4, 29.5, 29.6, 29.7, 29.79, 29.8, 30.0, 
32.0, 82.0, 126.1, 126.5, 126.6, 127.0, 127.3, 127.5, 127.56, 127.8, 130.0, 132.3, 133.9, 136.7, 
138.6, 138.8 and 152.5; mass spectrum (APCI), m/z 536.3556 (M+H)+ (C34H50NO2S requires 
536.3562).  
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tert-Butyl 2-Pentyl-10H-phenothiazine-10-carboxylate (45). A sample containing 1.90 g (5.31 
mmol) of 36 was dissolved in 20 mL of 7:3 ethanol-dichloromethane and purged with argon for 
20 min. To the resulting solution was added 0.11 g of 10% palladium-on-carbon. The suspension 
was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The reaction mixture 
was then filtered through a Celite pad. The filtrate was concentrated under diminished pressure. 
The residue was purified on a silica gel column (20 × 3 cm). Elution with 4:1 hexane-
dichloromethane afforded 45 as a colorless oil: yield 1.70 g (87%); silica gel TLC Rf  0.62 (9:1 
hexane-dichloromethane); 1H NMR (CD3OD) δ 0.76 (s, 3H), 1.16 (s, 4H), 1.32 (s, 9H), 1.45 (s, 
2H), 2.41 (s, 2H), 6.77 (s, 1H), 6.94 (s, 1H), 7.05 (m, 2H), 7.14 (s, 1H), 7.23 (s, 1H) and 7.38 (s, 
1H); 13C NMR (CD3OD) δ 14.6, 23.4, 28.5, 32.1, 32.3, 36.3, 82.8, 127.0, 127.46, 127.47, 128.0, 
128.2, 128.3, 129.9, 133.5, 139.7, 139.9, 142.7 and 153.6; mass spectrum (APCI), m/z 370.1842 
(M+H)+ (C22H28NO2S requires 370.1841). 
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tert-Butyl 2-Octyl-10H-phenothiazine-10-carboxylate (46). A sample containing 0.90 g (2.20 
mmol) of 37 was dissolved in 20 mL of 7:3 ethanol-dichloromethane and purged with argon for 
20 min. To the resulting solution was added 0.05 g of 10% palladium-on-carbon. The suspension 
was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The reaction mixture 
was then filtered through a Celite pad. The filtrate was concentrated under diminished pressure. 
The residue was purified on a silica gel column (20 × 3 cm). Elution with 3:2 hexane-
dichloromethane afforded 46 as a colorless oil: yield 0.90 g (98%); silica gel TLC Rf  0.50 (3:2 
hexane-dichloromethane); 1H NMR (CDCl3) δ 0.99 (t, 3H, J = 7.5 Hz), 1.39 (d, 10H, J = 20 
Hz), 1.57 (s, 9H), 1.71 (m, 2H), 2.68 (t, 2H, J = 7.5 Hz), 7.01 (d, 1H, J = 10 Hz), 7.14 (t, 1H, J 
= 7.5 Hz), 7.28 (t, 2H, J = 7.5 Hz), 7.36 (d, 1H, J = 10 Hz), 7.47 (s, 1H) and 7.62 (d, 1H, J = 10 
Hz); 13C NMR (CDCl3) δ 13.9, 22.5, 27.9, 29.0, 29.1, 29.3, 31.3, 31.7, 35.4, 81.4, 125.7, 126.0, 
126.1, 126.8, 127.0, 127.01, 127.1, 128.6, 132.2, 138.5, 138.7, 141.4 and 152.1; mass spectrum 
(APCI), m/z 412.2300 (M+H)+ (C25H33NO2S requires 412.2305). 
 
tert-Butyl 2-Nonyl-10H-phenothiazine-10-carboxylate (47). A sample containing 1.10 g (2.60 
mmol) of 38 was dissolved in 20 mL of 7:3 ethanol-dichloromethane and purged with argon for 
20 min. To the resulting solution was added 0.06 g of 10% palladium-on-carbon. The suspension 
was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The reaction mixture 
was then filtered through a Celite pad. The filtrate was concentrated under diminished pressure. 
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The residue was purified on a silica gel column (20 × 3 cm). Elution with 4:1 hexane-
dichloromethane afforded 47 as a colorless oil: yield 1.10 g (99%); silica gel TLC Rf 0.70 (1:1 
hexane-dichloromethane); 1H NMR (CDCl3) δ 0.95 (t, 3H, J = 7.5 Hz), 1.35 (d, 12H, J = 20 
Hz), 1.54 (s, 9H), 1.67 (m, 2H), 2.65 (t, 2H, J = 10 Hz), 6.99 (d, 1H, J = 10 Hz), 7.13 (t, 1H, J = 
10 Hz), 7.26 (t, 2H, J = 10 Hz), 7.34 (d, 1H, J = 10 Hz), 7.43 (s, 1H) and 7.58 (d, 1H, J = 10 
Hz); 13C NMR (CDCl3) δ 14.1, 22.6, 28.1, 29.2, 29.3, 29.4, 29.5, 31.4, 31.8, 35.5, 81.6, 125.8, 
126.2, 126.3, 127.0, 127.11, 127.13, 127.3, 128.7, 132.4, 138.6, 138.8, 141.6 and 152.3; mass 
spectrum (APCI), m/z 426.2425 (M+H)+ (C26H35NO2S requires 426.2461). 
 
tert-Butyl 2-Decyl-10H-phenothiazine-10-carboxylate (48). A sample containing 2.43 g (5.57 
mmol) of 39 was dissolved in 20 mL of 7:3 ethanol-dichloromethane and purged with argon for 
20 min. To the resulting solution was added 0.12 g of 10% palladium-on-carbon. The suspension 
was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The reaction mixture 
was then filtered through a Celite pad. The filtrate was concentrated under diminished pressure. 
The residue was purified on a silica gel column (20 × 3 cm). Elution with 6:1 hexane-
dichloromethane afforded 48 as a colorless oil: yield 0.36 g (15%); silica gel TLC Rf 0.80 (1:1 
hexane-dichloromethane); 1H NMR (CDCl3) δ 0.96 (t, 3H, J = 7.5 Hz), 1.34 (s, 14H), 1.56 (s, 
9H), 1.68 (m, 2H), 2.67 (t, 2H, J = 7.5 Hz), 7.02 (d, 1H, J = 10 Hz), 7.16 (t, 1H, J = 7.5 Hz), 
7.29 (t, 2H, J = 10 Hz), 7.37 (d, 1H, J = 5 Hz), 7.44 (s, 1H) and 7.59 (d, 1H, J = 5 Hz); 13C 
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NMR (CDCl3) δ 14.1, 22.7, 28.1, 29.2, 29.3, 29.51, 29.58, 29.6, 31.5, 31.9, 35.6, 81.7, 125.9, 
126.2, 126.3, 127.0, 127.1, 127.2, 127.3, 128.7, 132.4, 138.6, 138.8, 141.7 and 152.4; mass 
spectrum (APCI), m/z 440.2585 (M+H)+ (C27H37NO2S requires 440.2618). 
 
tert-Butyl 2-Undecyl-10H-phenothiazine-10-carboxylate (49). A sample containing 0.85 g 
(1.88 mmol) of 40 was dissolved in 10 mL of 7:3 ethanol-dichloromethane and purged with 
argon for 20 min. To the resulting solution was added 0.04 g of 10% palladium-on-carbon. The 
suspension was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The 
reaction mixture was then filtered through a Celite pad. The filtrate was concentrated under 
diminished pressure. The residue was purified on a silica gel column (20 × 1 cm). Elution with 
4:1 hexane-dichloromethane afforded 49 as a colorless oil: yield 0.55 g (80%); silica gel TLC Rf 
0.68 (1:1 hexane-dichloromethane); 1H NMR (CDCl3) δ 0.96 (t, 3H, J = 6.7 Hz), 1.35 (s, 16H), 
1.56 (s, 9H), 1.69 (m, 2H), 2.67 (t, 2H, J = 7.7 Hz), 7.02 (d, 1H, J = 8 Hz), 7.16 (t, 1H, J = 7.7 
Hz), 7.28 (d, 2H, J = 8 Hz), 7.37 (d, 1H, J = 8 Hz), 7.44 (s, 1H) and 7.60 (d, 1H, J = 7.5 Hz); 
13C NMR (CDCl3) δ 14.1, 22.6, 28.1, 29.2, 29.3, 29.5, 29.57, 29.6, 29.67, 31.4, 31.9, 35.5, 81.7, 
125.8, 126.2, 126.9, 127.0, 127.1, 127.19, 127.3, 128.7, 132.4, 138.6, 138.8, 141.6 and 152.4; 
mass spectrum (APCI), m/z 454.2772 (M+H)+ (C28H40NO2S requires 454.2780).  
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tert-Butyl 2-Tridecyl-10H-phenothiazine-10-carboxylate (50). A sample containing 1.60 g 
(3.34 mmol) of 41 was dissolved in 20 mL of 7:3 ethanol-dichloromethane and purged with 
argon for 20 min. To the resulting solution was added 0.07 g of 10% palladium-on-carbon. The 
suspension was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The 
reaction mixture was then filtered through a Celite pad. The filtrate was concentrated under 
diminished pressure. The residue was purified on a silica gel column (20 × 3 cm). Elution with 
4:1 hexane-dichloromethane afforded 50 as a colorless oil: yield 1.50 g (94%); silica gel TLC Rf 
0.68 (1:1 hexane-dichloromethane); 1H NMR (CDCl3) δ 0.97 (s, 3H), 1.35 (s, 20H), 1.56 (s, 9H), 
1.69 (s, 2H), 2.67 (s, 2H), 7.02 (d, 1H, J = 7 Hz), 7.17 (d, 1H, J = 6.5 Hz), 7.28 (d, 2H, J = 7.5 
Hz), 7.37 (d, 1H, J = 7 Hz), 7.45 (s, 1H) and 7.60 (d, 1H, J = 7 Hz); 13C NMR (CDCl3) δ 14.1, 
22.7, 28.1, 29.31, 29.39, 29.5, 29.6, 29.7, 31.5, 31.9, 35.6, 81.7, 125.9, 126.2, 127.0, 127.1, 
127.2, 127.30, 127.38, 128.8, 132.4, 138.6, 138.8, 141.6 and 152.4; mass spectrum (APCI), m/z 
482.3092 (M+H)+ (C30H44NO2S requires 482.3093). 
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tert-Butyl 2-Pentadecyl-10H-phenothiazine-10-carboxylate (51). A sample containing 2.00 g 
(3.94 mmol) of 42 was dissolved in 22 mL of 7:3 ethanol-dichloromethane and purged with 
argon for 20 min. To the resulting solution was added 0.08 g of 10% palladium-on-carbon. The 
suspension was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The 
reaction mixture was then filtered through a Celite pad. The filtrate was concentrated under 
diminished pressure. The residue was purified on a silica gel column (20 × 3 cm). Elution with 
4:1 hexane-dichloromethane afforded 51 as a colorless oil: yield 1.91 g (97%); silica gel TLC Rf 
0.68 (1:1 hexane-dichloromethane); 1H NMR (CDCl3) δ 0.95 (t, 3H, J = 7.5 Hz), 1.33 (s, 24H), 
1.55 (s, 9H), 1.68 (d, 2H, J = 5 Hz), 2.66 (t, 2H, J =7.5 Hz), 7.01 (d, 1H, J = 10 Hz), 7.15 (m, 
1H), 7.28 (m, 2H), 7.37 (t, 1H, J = 5 Hz), 7.43 (s, 1H) and 7.58 (d, 1H, J = 10 Hz); 13C NMR 
(CDCl3) δ 14.1, 22.7, 28.2, 29.3, 29.4, 29.5, 29.6, 29.74, 29.77, 31.5, 31.9, 35.6, 81.7, 125.9, 
126.30, 126.36, 127.0, 127.1, 127.2, 127.3, 128.8, 132.5, 138.6, 138.9, 141.7 and 152.4; mass 
spectrum (APCI), m/z 510.3416 (M+H)+ (C32H48NO2S requires 510.3406).  
 
tert-Butyl 2-Hexadecyl-10H-phenothiazine-10-carboxylate (52). A sample containing 1.27 g 
(2.43 mmol) of 43 was dissolved in 20 mL of 7:3 ethanol-dichloromethane and purged with 
argon for 20 min. To the resulting solution was added 0.05 g of 10% palladium-on-carbon. The 
suspension was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The 
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reaction mixture was then filtered through a Celite pad. The filtrate was concentrated under 
diminished pressure. The residue was purified on a silica gel column (20 × 3 cm). Elution with 
5:1 hexane-dichloromethane afforded 52 as a colorless oil: yield 1.20 g (94%); silica gel TLC Rf 
0.68 (1:1 hexane-dichloromethane); 1H NMR (CDCl3) δ 0.95 (t, 3H, J = 7.5 Hz), 1.32 (s, 26 H), 
1.55 (s, 9H), 1.67 (m, 2H), 2.65 (t, 2H, J = 7.5 Hz), 7.01 (d, 1H, J = 10 Hz), 7.16 (t, 1H, J = 7.5 
Hz), 7.28 (m, 2H), 7.36 (d, 1H, J = 5 Hz), 7.42 (s, 1H) and 7.58 (d, 1H, J = 10 Hz); 13C NMR 
(CDCl3) δ 14.2, 22.7, 28.2, 29.3, 29.4, 29.5, 29.6, 29.75, 29.78, 31.5, 32.0, 35.6, 81.8, 125.9, 
126.33, 126.39, 127.1, 127.21, 127.24, 127.4, 128.8, 132.5, 138.7, 138.9, 141.7 and 152.5; mass 
spectrum (APCI), m/z 524.3550 (M+H)+ (C33H50NO2S requires 524.3562).  
 
tert-Butyl 2-Heptadecyl-10H-phenothiazine-10-carboxylate (53). A sample containing 0.14 g 
(0.25 mmol) of 44 was dissolved in 10 mL of 7:3 ethanol-dichloromethane and purged with 
argon for 20 min. To the resulting solution was added 0.01 g of 10% palladium-on-carbon. The 
suspension was stirred at room temperature under an atmosphere of H2 (40 psi) for 2 h. The 
reaction mixture was then filtered through a Celite pad. The filtrate was concentrated under 
diminished pressure. The residue was purified on a silica gel column (20 × 1 cm). Elution with 
4:1 hexane-dichloromethane afforded 53 as a colorless oil: yield 0.14 g (93%); silica gel TLC Rf 
0.84 (9:1 hexane-dichloromethane); 1H NMR (CDCl3) δ 0.88 (t, 3H, J = 6.8 Hz), 1.26 (s, 28H), 
1.49 (s, 9H), 1.60 (m, 2H), 2.59 (t, 2H, J = 7.6 Hz), 6.96 (dd, 1H, J = 1.6 Hz), 7.12 (t, 1H, J = 
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7.4 Hz), 7.25 (m, 2H), 7.32 (dd, 1H, J = 1.2 Hz), 7.35 (d, 1H, J = 1.2 Hz) and 7.52 (d, 1H, J = 8 
Hz); 13C NMR (CDCl3) δ 14.1, 22.7, 28.1, 29.3, 29.4, 29.5, 29.6, 29.7, 29.78, 31.5, 31.9, 35.6, 
81.7, 125.8, 126.2, 126.3, 127.0, 127.1, 127.19, 127.3, 128.8, 132.4, 138.6, 138.8, 141.6 and 
152.4; mass spectrum (APCI), m/z 538.3723 (M+H)+ (C34H52NO2S requires 538.3719). 
 
N-(7-(Dimethylamino)-2-pentyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (1). A sample containing 1.70 g (4.60 mmol) of 45 was dissolved in 20 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 2.81 mL (4.18 g, 36.8 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 0.18 g (0.66 mmol) of the crude residue in 5 mL of dichloromethane 
was added 0.54 g (2.14 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 1.70 mL (1.14 g, 3.34 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with 1:1 
methanol-acetonitrile afforded 1 as a blue solid: yield 0.04 g (25%); silica gel TLC Rf  0.23 
(acetonitrile); 1H NMR (CDCl3) δ 0.85 (t, 3H, J = 6.5 Hz), 1.33 (s, 4H), 1.64 (s, 2H), 2.60 (s, 
3H), 2.80 (s, 2H), 3.41 (d, 9H, J = 64.5 Hz), 7.29 (s, 2H), 7.79 (d, 2H, J = 49.5 Hz) and 8.67 (s, 
1H); 13C NMR (CDCl3) δ 13.9, 22.3, 29.7, 31.5, 33.8, 34.8, 44.6, 106.9, 111.0, 119.9, 131.5, 
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135.2, 136.7, 137.0, 137.1, 138.4, 138.7, 153.8 and 157.8; mass spectrum (ESI), m/z 354.1997 
(M)+ (C21H28N3S requires 354.2004); ultraviolet/visible spectrum λmax 665 nm (CH2Cl2), λmax 
665 nm (MeOH). 
 
N-(7-(Dimethylamino)-2-octyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (28). A sample containing 1.00 g (2.44 mmol) of 46 was dissolved in 20 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.50 mL (2.23 g, 19.5 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 0.35 g (1.13 mmol) of the crude residue in 10 mL of dichloromethane 
was added 0.92 g (3.61 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 2.82 mL (1.88 g, 5.65 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with 1:1 ethyl 
acetate-methanol afforded 28 as a blue solid: yield 0.33 g (56%); silica gel TLC Rf  0.50 (1:1 
ethyl acetate-methanol); 1H NMR (CDCl3) δ 0.82 (s, 3H), 1.22 (s, 10H), 1.65 (s, 2H), 2.63 (s, 
4H), 2.81 (s, 2H), 3.43 (d, 8H, J = 70 Hz), 7.36 (s, 1H), 7.84 (d, 2H, J = 50 Hz) and 8.63 (s, 2H); 
13C NMR (CDCl3) δ 14.0, 22.5, 29.0, 29.2, 29.3, 30.0, 31.6, 34.8, 42.5, 44.5, 106.9, 111.1, 119.9, 
131.6, 135.3, 136.8, 137.1, 137.2, 138.4, 138.8, 153.9 and 157.9; mass spectrum (ESI), m/z 
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396.2452 (M)+ (C24H34N3S requires 396.2468); ultraviolet/visible spectrum λmax 648.5 nm 
(CH2Cl2), λmax 662.5 nm (MeOH).   
 
N-(7-(Dimethylamino)-2-nonyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (26). A sample containing 0.91 g (2.14 mmol) of 47 was dissolved in 22 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.30 mL (1.93 g, 17.2 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 0.49 g (1.51 mmol) of the crude residue in 14 mL of dichloromethane 
was added 1.22 g (4.83 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 3.77 mL (2.52 g, 7.55 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with 1:1 ethyl 
acetate-methanol afforded 26 as a blue solid: yield 0.35 g (43%); silica gel TLC Rf  0.50 (1:1 
ethyl acetate-methanol); 1H NMR (CDCl3) δ 0.73 (t, 3H, J = 5 Hz), 1.13 (s, 12H), 1.56 (s, 2H), 
2.54 (s, 3H), 2.74 (s, 2H), 3.34 (d, 9H, J = 60 Hz), 7.24 (d, 2H, J = 35 Hz), 7.69 (d, 2H, J = 55 
Hz) and 8.61 (s, 1H); 13C NMR (CDCl3) δ 13.6, 22.1, 28.7, 28.95, 28.98, 29.7, 31.3, 33.5, 34.4, 
42.3, 44.3, 106.5, 110.6, 119.6, 131.0, 134.7, 136.2, 136.5, 136.7, 137.9, 138.3, 153.4 and 157.3; 
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mass spectrum (ESI), m/z 410.2607 (M)+ (C25H36N3S requires 410.2624); ultraviolet/visible 
spectrum λmax 617.5 nm (CH2Cl2), λmax 653 nm (MeOH). 
 
N-(7-(Dimethylamino)-2-decyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (24). A sample containing 0.87 g (1.98 mmol) of 48 was dissolved in 20 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.21 mL (1.80 g, 15.9 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 0.46 g (1.36 mmol) of the crude residue in 14 mL of dichloromethane 
was added 1.10 g (4.35 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 3.40 mL (2.27 g, 6.80 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with 1:1 ethyl 
acetate-methanol afforded 24 as a blue solid: yield 0.46 g (61%); silica gel TLC Rf  0.50 (1:1 
ethyl acetate-methanol); 1H NMR (CDCl3) δ 0.66 (t, 3H, J = 7.5 Hz), 1.05 (s, 16H), 1.49 (s, 2H), 
2.50 (s, 4H), 2.66 (s, 2H), 3.26 (d, 6H, J = 60 Hz), 7.17 (d, 1H, J = 45 Hz), 7.54 (s, 1H), 7.65 (s, 
1H) and 8.51 (s, 2H); 13C NMR (CDCl3) δ 13.4, 21.8, 28.4, 28.6, 28.7, 29.4, 31.0, 33.2, 34.3, 
34.4, 42.1, 44.1, 106.2, 110.3, 119.4, 130.6, 134.3, 135.9, 136.2, 136.3, 137.6, 138.0, 153.1 and 
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156.9; mass spectrum (ESI), m/z 424.2763 (M)+ (C26H38N3S requires 424.2781); 
ultraviolet/visible spectrum λmax 664 nm (CH2Cl2), λmax 663.5 nm (MeOH).   
 
N-(7-(Dimethylamino)-2-undecyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (2). A sample containing 0.82 g (1.81 mmol) of 49 was dissolved in 12 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.10 mL (1.63 g, 14.5 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 1.40 g (4.00 mmol) of the crude residue in 20 mL of dichloromethane 
was added 3.20 g (12.9 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 10.1 mL (6.70 g, 20.3 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with methanol 
afforded 2 as a blue-green solid: yield 0.10 g (25%); silica gel TLC Rf  0.07 (methanol); 
1H NMR 
(CDCl3) δ 0.88 (t, 3H, J = 6.7 Hz), 1.26 (s, 18H), 1.72 (m, 2H), 2.85 (t, 2H, J = 7.7 Hz), 3.35 (s, 
4H), 3.46 (s, 5H), 3.56 (s, 1H), 7.28 (d, 1H, J = 12.5 Hz), 7.37 (s, 1H), 7.39 (s, 1H), 7.87 (s, 1H) 
and 7.97 (d, 1H, J = 10Hz); 13C NMR (CDCl3) δ 14.2, 22.7, 29.4, 29.5, 29.6, 29.7, 29.73, 30.2, 
32.0, 34.2, 42.5, 44.8, 106.8, 111.2, 119.9, 132.0, 135.7, 137.1, 137.3, 137.4, 138.7, 138.8, 154.2 
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and 158.2; mass spectrum (ESI), m/z 438.2948 (M)+ (C27H40N3S requires 438.2943); 
ultraviolet/visible spectrum λmax 670 nm (CH2Cl2), λmax  665 nm (MeOH). 
 
N-(7-(Dimethylamino)-2-tridecyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (3). A sample containing 1.50 g (3.11 mmol) of 50 was dissolved in 20 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.90 mL (2.81 g, 24.9 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 1.40 g (3.67 mmol) of the crude residue in 20 mL of dichloromethane 
was added 3.00 g (11.7 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 9.20 mL (6.16 g, 18.3 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with 1:1 ethyl 
acetate-methanol afforded 3 as a blue solid: yield 0.90 g (43%); silica gel TLC Rf  0.03 
(methanol); 1H NMR (CDCl3) δ 0.82 (d, 3H, J = 6 Hz), 1.21 (s, 20H), 1.66 (s, 2H), 2.63 (s, 4H), 
2.82 (s, 2H), 3.35 (s, 4H), 3.49 (s, 4H), 7.37 (s, 2H), 7.80 (s, 1H), 7.90 (d, 1H, J = 1.5 Hz) and 
8.63 (s, 1H); 13C NMR (CDCl3) δ 14.0, 22.6, 29.2, 29.3, 29.4, 29.56, 29.59, 29.61, 29.63, 30.1, 
31.8, 34.0, 34.8, 42.5, 44.6, 107.0, 111.1, 119.8, 131.7, 135.4, 136.8, 137.1, 137.2, 138.5, 138.8, 
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154.0 and 157.9; mass spectrum (ESI), m/z 466.3250 (M+) (C29H44N3S requires 466.3256). 
ultraviolet/visible spectrum λmax 667 nm (CH2Cl2), λmax 663 nm (MeOH).    
 
N-(7-(Dimethylamino)-2-pentadecyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (4). A sample containing 1.89 g (3.71 mmol) of 51 was dissolved in 25 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 2.30 mL (3.42 g, 24.7 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 3.00 g (7.33 mmol) of the crude residue in 25 mL of dichloromethane 
was added 5.95 g (23.4 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 18.3 mL (12.2 g, 36.6 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with 1:1 ethyl 
acetate-methanol afforded 4 as a blue solid: yield 0.39 g (15%); silica gel TLC Rf  0.06 
(methanol); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 5 Hz), 1.25 (s, 24H), 1.71 (m, 2H), 2.79 (s, 4H), 
2.84 (t, 2H, J = 7.5 Hz), 3.34 (s, 4H), 3.48 (s, 4H), 7.27 (s, 1H), 7.38 (s, 1H), 7.41 (s, 1H), 7.88 
(s, 1H) and 7.99 (d, 1H, J = 10 Hz); 13C NMR (CDCl3) δ 14.2, 22.7, 29.4, 29.5, 29.6, 29.7, 30.2, 
32.0, 34.2, 35.1, 42.6, 44.7, 106.9, 111.3, 119.8, 132.0, 135.8, 137.1, 137.3, 137.4, 138.7, 138.9, 
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154.2 and 158.2; mass spectrum (ESI), m/z 494.3576 (M)+ (C31H48N3S requires 494.3563); 
ultraviolet/visible spectrum λmax  664 nm (CH2Cl2), λmax 665 nm (MeOH).   
 
N-(7-(Dimethylamino)-2-hexadecyl-3H-phenothiazin-3-ylidene)-N-methylmethanaminium 
iodide (22). A sample containing 1.23 g (2.35 mmol) of 52 was dissolved in 20 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.43 mL (2.13 g, 18.8 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 1.15 g (2.71 mmol) of the crude residue in 20 mL of dichloromethane 
was added 2.20 g (8.67 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 6.70 mL (4.48 g, 13.5 mmol) of 2 M 
dimethylamine in THF and the reaction mixture was stirred at room temperature for 4 h. The 
greenish blue mixture was purified on a silica gel column (20 × 3 cm). Elution with 1:1 ethyl 
acetate-methanol afforded 22 as a blue solid: yield 0.36 g (24%); silica gel TLC Rf  0.06 
(methanol); 1H NMR (CDCl3) δ 0.84 (t, 3H, J = 7.5 Hz), 1.22 (s, 26H), 1.67 (s, 1H), 2.67 (s, 
4H), 2.83 (s, 2H), 3.36 (s, 5H), 3.52 (d, 4H, J = 20 Hz), 7.37 (s, 2H), 7.83 (s, 1H), 7.93 (s, 1H) 
and 8.58 (s, 1H); 13C NMR (CDCl3) δ 14.1, 22.6, 29.3, 29.4, 29.5, 29.64, 29.68, 29.7, 30.1, 31.9, 
34.1, 35.0, 42.6, 44.6, 107.0, 111.2, 119.9, 131.8, 135.5, 136.9, 137.1, 137.4, 138.6, 138.9, 154.1 
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and 158.1; mass spectrum (ESI), m/z 508.3734 (M)+ (C32H50N3S requires 508.3720); 
ultraviolet/visible spectrum λmax  667 nm (CH2Cl2), λmax 664 nm (MeOH). 
 
N-(4,7-Bis(morpholino)-2-heptadecyl-3H-phenothiazin-3-ylidene)-N-morpholinium iodide 
(9). A sample containing 0.11 g (0.19 mmol) of 53 was dissolved in 10 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 0.12 mL (0.18 g, 1.59 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 10 mL of saturated sodium bicarbonate solution, extracted with two 15- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 0.20 g (0.45 mmol) of the crude residue in 7 mL of dichloromethane 
was added 0.38 g (1.46 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 0.20 mL (0.20 g, 2.28 mmol) of morpholine 
and the reaction mixture was stirred at room temperature for 4 h. The dark violet mixture was 
purified on a silica gel column (20 × 3 cm). Elution with 1:1 ethyl acetate-methanol afforded 9 as 
a violet solid: yield 0.10 g (27%); silica gel TLC Rf  0.48 (1:1 ethyl acetate-methanol); 
1H NMR 
(CDCl3) δ 0.85 (t, 3H, J = 6.7 Hz), 1.23 (s, 30H), 1.70 (m, 2H), 2.68 (t, 2H, J = 8 Hz), 3.18 (t, 
3H, J = 4.5 Hz), 3.27 (t, 2H, J = 5 Hz), 3.78 (t, 3H, J = 4.5 Hz), 3.88 (t, 3H, J = 4.5 Hz), 3.93 (t, 
4H, J = 4.7 Hz), 3.98 (t, 3H, J = 4.5 Hz), 4.04 (s, 3H), 4.12 (t, 1H,  J = 5 Hz), 6.51 (d, 1H, J = 
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2.5 Hz), 7.29 (s, 1H) and 7.69 (s, 2H); 13C NMR (CDCl3) δ 14.2, 22.8, 29.4, 29.5, 29.8, 30.4, 
31.3, 32.0, 42.9, 49.5, 52.3, 52.8, 62.9, 66.8, 66.9, 101.9, 107.2, 114.2, 127.5, 134.5, 136.2, 
136.6, 137.3, 138.8, 155.5, 156.9 and 157.0; mass spectrum (ESI), m/z 691.4608 (M)+ 
(C41H63N4O3S requires 691.4621); ultraviolet/visible spectrum λmax 590 nm (CH2Cl2), λmax 575 
nm (MeOH).  
 
1-(2-Octyl-7-(piperidin-1-yl)-3H-phenothiazin-3-ylidene)piperidin-1-ium iodide (30). A 
sample containing 1.00 g (2.44 mmol) of 46 was dissolved in 20 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.50 mL (2.23 g, 19.5 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 0.35 g (1.13 mmol) of the crude residue in 10 mL of dichloromethane 
was added 0.92 g (3.61 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 0.56 mL (0.48 g, 5.65 mmol) of piperidine 
and the reaction mixture was stirred at room temperature for 4 h. The greenish blue mixture was 
purified on a silica gel column (20 × 3 cm). Elution with 4:1 ethyl acetate-methanol afforded 30 
as a blue-green solid: yield 0.64 g (94%); silica gel TLC Rf  0.50 (4:1 ethyl acetate-methanol); 
1H 
NMR (CDCl3) δ 0.82 (s, 3H), 1.22 (s, 11H), 1.69 (s, 3H), 1.79 (d, 7H, J = 25 Hz), 1.97 (d, 2H, J 
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= 10 Hz), 2.70 (d, 3H, J = 25 Hz), 3.35 (s, 3H), 3.87 (s, 3H), 4.06 (t, 2H, J = 5 Hz), 7.34 (d, 1H, 
J = 25 Hz), 7.54 (s, 1H) and 7.86 (t, 3H, J = 45 Hz); 13C NMR (CDCl3) δ 13.9, 22.4, 23.6, 25.9, 
26.7, 28.9, 29.1, 29.3, 30.1, 31.5, 31.9, 45.7, 50.6, 53.1, 60.1, 107.0, 113.1, 121.3, 129.6, 136.5, 
136.8, 136.9, 138.5, 139.3, 152.9, 158.2 and 170.9; mass spectrum (ESI), m/z 476.3085 (M)+ 
(C30H42N3S requires 476.3094); ultraviolet/visible spectrum λmax 682 nm (CH2Cl2), λmax 670 nm 
(MeOH).  
 
N-(7-(Diethylamino)-2-undecyl-3H-phenothiazin-3-ylidene)-N-ethylmethanaminium iodide 
(32). A sample containing 0.82 g (1.81 mmol) of 49 was dissolved in 12 mL of anhydrous 
dichloromethane. To the resulting solution was added dropwise 1.10 mL (1.63 g, 14.5 mmol) of 
trifluoroacetic acid. The reaction mixture was stirred at room temperature for 18 h. The reaction 
was then quenched with 20 mL of saturated sodium bicarbonate solution, extracted with two 30- 
mL portions of dichloromethane, dried over anhydrous Na2SO4 and then concentrated under 
diminished pressure. The crude residue was utilized for the next step without further purification. 
To a solution containing 0.23 g (0.64 mmol) of the crude residue in 7 mL of dichloromethane 
was added 0.52 g (2.04 mmol) of iodine and the reaction mixture was stirred in the dark for 15 
min. To the resulting solution was added dropwise 0.33 mL (0.23 g, 3.20 mmol) of diethylamine 
and the reaction mixture was stirred at room temperature for 4 h. The greenish blue mixture was 
purified on a silica gel column (20 × 3 cm). Elution with 9:1 ethyl acetate-methanol afforded 32 
as a blue solid: yield 0.27 g (67%); silica gel TLC Rf  0.50 (9:1 ethyl acetate-methanol); 
1H NMR 
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(CDCl3) δ 0.71 (s, 3H), 1.14 (d, 15H, J = 35 Hz), 1.29 (s, 3H), 1.40 (s, 8H), 1.56 (s, 2H), 2.66 (d, 
2H, J = 20 Hz), 2.99 (s, 5H), 3.47 (s, 2H), 3.69 (s, 2H), 3.92 (s, 1H), 7.28 (d, 1H, J = 50 Hz), 
7.57 (d, 1H, J = 65 Hz), 7.80 (d, 1H, J = 50 Hz) and 8.09 (s, 2H); 13C NMR (CDCl3) δ 10.8, 
12.9, 13.6, 22.0, 28.68, 28.69, 28.7, 28.83, 28.87, 28.89, 28.9, 29.0, 29.6, 31.25, 31.27, 33.0, 
42.6, 46.8, 47.0, 105.8, 111.9, 119.7, 130.0, 135.6, 136.1, 137.1, 137.8, 138.8, 152.2 and 156.1; 
mass spectrum (ESI), m/z 494.3558 (M)+ (C31H48N3S requires 494.3563); ultraviolet/visible 
spectrum λmax 651 nm (CH2Cl2), λmax 667.5 nm (MeOH). 
 
7-(Dimethylamino)-2-pentyl-3H-phenothiazin-3-one (11).  To a solution of 0.65 g (1.85 
mmol) of 1 in 10 mL of 6:1 tetrahydrofuran-water was added 0.10 g (1.85 mmol) of potassium 
hydroxide. The reaction mixture was stirred at 70 oC for 30 min under an open-air atmosphere at 
which time the solution had changed from green to red in color. The reaction mixture was then 
quenched with 20 mL of water. The product was extracted with two 30-mL portions of ethyl 
acetate. The organic phase was washed with 20 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 1 
cm). Elution with ethyl acetate afforded 11 as a red solid: yield 0.02 g (5%); silica gel TLC Rf  
0.16 (4:1 hexane-ethyl acetate); 1H NMR (CDCl3) δ 0.91 (t, 3H, J = 7 Hz), 1.37 (m, 4H), 1.71 
(m, 2H), 2.70 (t, 2H, J = 8 Hz), 2.87 (s, 6H), 6.71 (d, 1H, J = 2 Hz), 6.88 (dd, 1H, J = 2.2 Hz), 
6.91 (s, 1H), 7.58 (d, 1H, J = 10 Hz) and 7.70 (s, 1H); 13C NMR (CDCl3) δ 14.1, 22.6, 29.7, 
31.5, 31.9, 44.0, 112.8, 119.2, 123.3, 133.9, 134.5, 135.4, 136.3, 139.7, 143.2, 155.8 and 182.4; 
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mass spectrum (APCI), m/z 327.1534 (M+H)+  (C19H23N2OS requires 327.1531); 
ultraviolet/visible spectrum λmax 545 nm (CH2Cl2), λmax 570 nm (MeOH).  
 
7-(Dimethylamino)-2-octyl-3H-phenothiazin-3-one (29).  To a solution of 0.33 g (0.83 mmol) 
of 28 in 14 mL of 6:1 tetrahydrofuran-water was added 0.05 g (0.83 mmol) of potassium 
hydroxide. The reaction mixture was stirred at room temperature for 30 min under an open-air 
atmosphere at which time the solution had changed from green to red in color. The reaction 
mixture was then quenched with 20 mL of water. The product was extracted with two 30-mL 
portions of ethyl acetate. The organic phase was washed with 20 mL of brine, dried over 
anhydrous Na2SO4 and concentrated under diminished pressure. The residue was purified on a 
silica gel column (20 × 1 cm). Elution with 1:1 hexane-ethyl acetate afforded 29 as a red solid: 
yield 0.01 g (5%); silica gel TLC Rf  0.50 (1:1 hexane-ethyl acetate); 
1H NMR (CDCl3) δ 0.88 (t, 
3H, J = 7.5 Hz), 1.28 (m, 9H), 1.70 (m, 5H), 2.70 (t, 2H, J = 7.5 Hz), 2.88 (s, 4H), 6.73 (d, 1H, J 
= 2 Hz), 6.89 (dd, 1H, J = 2.2 Hz), 6.92 (s, 1H), 6.59 (d, 1H, J = 10 Hz) and 7.70 (s, 1H); 13C 
NMR (CDCl3) δ 14.2, 22.8, 29.3, 29.5, 29.8, 30.1, 31.6, 32.0, 44.0, 112.8, 119.1, 123.4, 133.8, 
134.8, 135.4, 135.5, 136.4, 139.7, 143.2, 155.8 and 182.2; mass spectrum (APCI), m/z 369.2030 
(M+H)+  (C22H28N2OS requires 369.1995); ultraviolet/visible spectrum λmax 548.5 nm (CH2Cl2), 
λmax 568 nm (MeOH). 
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7-(Dimethylamino)-2-nonyl-3H-phenothiazin-3-one (27).  To a solution of 0.35 g (0.84 mmol) 
of 26 in 14 mL of 6:1 tetrahydrofuran-water was added 0.05 g (0.84 mmol) of potassium 
hydroxide. The reaction mixture was stirred at room temperature for 30 min under an open-air 
atmosphere at which time the solution had changed from green to red in color. The reaction 
mixture was then quenched with 20 mL of water. The product was extracted with two 30-mL 
portions of ethyl acetate. The organic phase was washed with 20 mL of brine, dried over 
anhydrous Na2SO4 and concentrated under diminished pressure. The residue was purified on a 
silica gel column (20 × 1 cm). Elution with 1:1 hexane-ethyl acetate afforded 27 as a red solid: 
yield 0.02 g (14%); silica gel TLC Rf  0.50 (1:1 hexane-ethyl acetate); 
1H NMR (CDCl3) δ 0.87 
(t, 3H, J = 7.5 Hz), 1.26 (s, 13H), 1.69 (m, 2H), 2.69 (t, 2H, J = 10 Hz), 2.87 (s, 5H), 6.69 (d, 
1H, J = 5 Hz), 8.86 (dd, 1H, J = 2 Hz), 6.90 (s, 1H), 7.56 (d, 1H, J = 10 Hz) and 7.68 (s, 1H); 
13C NMR (CDCl3) δ 14.2, 22.7, 29.4, 29.60, 29.64, 29.7, 30.0, 31.6, 32.0, 43.9, 112.7, 119.1, 
123.3, 133.8, 134.5, 135.4, 136.3, 139.6, 143.1, 155.8 and 182.3; mass spectrum (APCI), m/z 
383.2172 (M+H)+  (C23H30N2OS requires 383.2152); ultraviolet/visible spectrum λmax 545.5 nm 
(CH2Cl2), λmax 564.5 nm (MeOH).  
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7-(Dimethylamino)-2-decyl-3H-phenothiazin-3-one (25).  To a solution of 0.46 g (1.10 mmol) 
of 24 in 14 mL of 6:1 tetrahydrofuran-water was added 0.06 g (1.10 mmol) of potassium 
hydroxide. The reaction mixture was stirred at room temperature for 30 min under an open-air 
atmosphere at which time the solution had changed from green to red in color. The reaction 
mixture was then quenched with 20 mL of water. The product was extracted with two 30-mL 
portions of ethyl acetate. The organic phase was washed with 20 mL of brine, dried over 
anhydrous Na2SO4 and concentrated under diminished pressure. The residue was purified on a 
silica gel column (20 × 1 cm). Elution with 3:2 hexane-ethyl acetate afforded 25 as a red sticky 
solid: yield 0.02 g (5%); silica gel TLC Rf  0.50 (3:2 hexane-ethyl acetate); 
1H NMR (CDCl3) δ 
0.87 (t, 3H, J = 7.5 Hz), 1.26 (s, 16H), 1.70 (m, 2H), 2.70 (t, 2H, J = 7.5 Hz), 2.88 (s, 4H), 6.73 
(d, 1H, J = 5 Hz), 6.89 (dd, 1H, J = 2 Hz), 6.92 (s, 1H), 7.59 (d, 1H, J = 10 Hz) and 7.70 (s, 
1H); 13C NMR (CDCl3) 14.2, 22.8. 29.4, 29.6, 29.71, 29.74, 29.79, 30.1, 31.6, 32.0, 44.0, 112.8, 
119.1, 123.4, 133.8, 134.6, 135.4, 135.5, 136.4, 139.7, 143.2, 155.8 and 182.2; mass spectrum 
(APCI), m/z 397.2310(M+H)+  (C24H32N2OS requires 397.2308); ultraviolet/visible spectrum 
λmax 546.5 nm (CH2Cl2), λmax 568 nm (MeOH).   
 
7-(Dimethylamino)-2-undecyl-3H-phenothiazin-3-one (12). To a solution of 0.08 g (0.18 
mmol) of 2 in 4 mL of 6:1 tetrahydrofuran-water was added 0.01 g (0.18 mmol) of potassium 
hydroxide. The reaction mixture was stirred at 25 oC for 30 min under an open-air atmosphere at 
which time the solution had changed from green to red in color. The reaction mixture was then 
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quenched with 10 mL of water. The product was extracted with two 10-mL portions of ethyl 
acetate. The organic phase was washed with 10 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 1 
cm). Elution with 1:1 hexane-ethyl acetate afforded 12 as a red solid: yield 7 mg (13%); silica 
gel TLC Rf  0.85 (ethyl acetate); 
1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7 Hz), 1.26 (s, 16H), 1.70 
(m, 2H), 2.70 (t, 2H, J = 8 Hz), 2.86 (s, 6H), 6.72 (d, 1H, J = 2 Hz), 6.88 (dd, 1H, J = 2 Hz), 
6.92 (s, 1H), 7.58 (d, 1H, J = 9.5 Hz) and 7.70 (s, 1H); 13C NMR (CDCl3) δ 14.2, 22.8, 29.4, 
29.6, 29.7, 29.8, 30.1, 31.6, 32.0, 44.0, 112.8, 119.2, 119.3, 123.3, 133.9, 134.5, 135.4, 136.4, 
139.7, 143.2, 155.8 and 182.4; mass spectrum (APCI), m/z 411.2463 (M+H)+  (C25H35N2OS 
requires 411.2470); ultraviolet/visible spectrum λmax 555 nm (CH2Cl2), λmax 565 nm (MeOH).   
 
7-(Dimethylamino)-2-tridecyl-3H-phenothiazin-3-one (13). To a solution of 0.78 g (1.68 
mmol) of 3 in 12 mL of 6:1 tetrahydrofuran-water was added 0.09 g (1.68 mmol) of potassium 
hydroxide. The reaction mixture was stirred at 25 oC for 30 min under an open-air atmosphere at 
which time the solution had changed from green to red in color. The reaction mixture was then 
quenched with 25 mL of water. The product was extracted with two 40-mL portions of ethyl 
acetate. The organic phase was washed with 25 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 1 
cm). Elution with 1:1 hexane-ethyl acetate afforded 13 as a red solid: yield 0.04 g (7%); silica 
gel TLC Rf  0.65 (1:1 hexane-ethyl acetate); 
1H NMR (CDCl3) δ 0.87 (t, 3H, J = 8.5 Hz), 1.25 (s, 
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20H), 1.70 (m, 2H), 2.57 (s, 1H), 2.70 (t, 2H, J = 7.5 Hz), 2.87 (s, 4H), 3.13 (s, 1H), 6.71 (d, 1H, 
J = 2 Hz), 6.88 (dd, 1H, J = 1.7 Hz), 6.91 (s, 1H), 7.58 (d, 1H, J = 10 Hz) and 7.69 (s, 1H); 13C 
NMR (CDCl3) δ 14.2, 22.8, 29.5, 29.6, 29.7, 29.8, 29.82, 29.83, 30.1, 31.6, 32.0, 44.0, 112.8, 
119.2, 123.3, 133.9, 134.5, 135.45, 135.46, 136.4, 139.7, 143.2, 155.8 and 182.4; mass spectrum 
(APCI), m/z 439.2777 (M+H)+  (C27H39N2OS requires 439.2783); ultraviolet/visible spectrum 
λmax 545 nm (CH2Cl2), λmax 566 nm (MeOH).   
 
7-(Dimethylamino)-2-pentadecyl-3H-phenothiazin-3-one (14). To a solution of 0.30 g (0.61 
mmol) of 4 in 12 mL of 6:1 tetrahydrofuran-water was added 0.04 g (0.61 mmol) of potassium 
hydroxide. The reaction mixture was stirred at 25 oC for 30 min under an open-air atmosphere at 
which time the solution had changed from green to red in color. The reaction mixture was then 
quenched with 25 mL of water. The product was extracted with two 40-mL portions of ethyl 
acetate. The organic phase was washed with 25 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 1 
cm). Elution with ethyl acetate afforded 14 as a red solid: yield 0.02 g (5%); silica gel TLC Rf  
0.65 (1:1 hexane-ethyl acetate); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.5 Hz), 1.25 (s, 25H), 1.70 
(m, 2H), 2.70 (t, 2H, J = 7.5 Hz), 2.88 (s, 5H), 6.72 (d, 1H, J = 2 Hz), 6.88 (dd, 1H, J = 3.5 Hz), 
6.91 (s, 1H), 7.58 (d, 1H, J = 10 Hz) and 7.70 (s, 1H); 13C NMR (CDCl3) δ 14.2, 22.8, 29.5, 
29.6, 29.7, 29.8, 29.8, 29.8, 30.1, 31.6, 32.0, 44.0, 112.8, 119.2, 123.3, 133.9, 134.5, 135.4, 
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136.4, 139.7, 143.2, 155.8 and 182.4; mass spectrum (APCI), m/z (M+H)+ 467.3084 
(C29H43N2OS requires 467.3096); ultraviolet/visible spectrum λmax  546 nm (CH2Cl2), λmax 566 
nm (MeOH).  
 
7-(Dimethylamino)-2-hexadecyl-3H-phenothiazin-3-one (23). To a solution of 0.31 g (0.61 
mmol) of 22 in 8 mL of 6:1 tetrahydrofuran-water was added 0.04 g (0.61 mmol) of potassium 
hydroxide. The reaction mixture was stirred at 25 oC for 30 min under an open-air atmosphere at 
which time the solution had changed from green to red in color. The reaction mixture was then 
quenched with 15 mL of water. The product was extracted with two 20-mL portions of ethyl 
acetate. The organic phase was washed with 15 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 1 
cm). Elution with 1:1 hexane-ethyl acetate afforded 23 as a red solid: yield 0.01 g (5%); silica 
gel TLC Rf  0.65 (1:1 hexane-ethyl acetate); 
1H NMR (CDCl3) δ 0.87 (t, 3H, J = 7.5 Hz), 1.25 (s, 
26H), 1.59 (s, 1H), 1.70 (m, 2H), 2.70 (t, 2H, J = 7.5 Hz), 2.88 (s, 5H), 6.72 (d, 1H, J = 2 Hz), 
6.88 (dd, 1H, J = 5 Hz), 6.92 (s, 1H), 7.58 (d, 1H, J = 10 Hz) and 7.70 (s, 1H); 13C NMR 
(CDCl3) δ 14.2, 22.8, 29.5, 29.6, 29.7, 29.81, 29.85, 30.1, 31.6, 32.0, 44.0, 112.8, 119.2, 123.3, 
134.0, 134.5, 135.4, 136.4, 139.7, 143.3, 155.8 and 182.4; mass spectrum (APCI), m/z 481.3250 
(M+H)+  (C30H45N2OS requires 481.3253); ultraviolet/visible spectrum λmax 545 nm (CH2Cl2), 
λmax 566 nm (MeOH). 
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4,7-Bis(morpholino)-2-heptadecyl-3H-phenothiazin-3-one (18). To a solution of 0.10 g (0.14 
mmol) of 9 in 8 mL of 6:1 tetrahydrofuran-water was added 0.01 g (0.14 mmol) of potassium 
hydroxide. The reaction mixture was stirred at 25 oC for 30 min under an open-air atmosphere at 
which time the solution had changed from green to red in color. The reaction mixture was then 
quenched with 15 mL of water. The product was extracted with two 20-mL portions of ethyl 
acetate. The organic phase was washed with 15 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 1 
cm). Elution with 4:1 hexane-ethyl acetate afforded 18 as a chocolate brown solid: yield 0.02 g 
(20%); silica gel TLC Rf  0.37 (ethyl acetate); 
1H NMR (CDCl3) δ 0.87 (t, 3H, J = 6.7 Hz), 1.25 
(s, 32H), 1.68 (m, 2H), 2.66 (t, 2H, J = 8 Hz), 2.99 (t, 3H, J = 4.5 Hz), 3.37 (t, 3H, J = 4 Hz), 
3.87 (t, 3H, J = 4 Hz), 3.95 (t, 3H, J = 4.2 Hz), 6.11 (s, 1H), 6.53 (s, 1H), 6.93 (s, 1H) and 7.57 
(s, 1H); 13C NMR (CDCl3) δ 14.2, 22.8, 29.5, 29.6, 29.8, 30.5, 32.0, 51.8, 52.7, 66.7, 67.1, 114.6, 
115.4, 119.8, 122.9, 133.9, 134.1, 135.1, 137.5, 141.1, 154.3, 156.0 and 182.3; mass spectrum 
(APCI), m/z 622.4033 (M+H)+ (C37H56N3O3S requires 622.4042); ultraviolet/visible spectrum 
λmax  475 nm (CH2Cl2), λmax 475 nm (MeOH).  
 
100 
 
2-Octyl-7-(piperidin-1-yl)-3H-phenothiazin-3-one (31). To a solution of 0.64 g (1.35 mmol) of 
30 in 28 mL of 6:1 tetrahydrofuran-water was added 0.08 g (1.35 mmol) of potassium hydroxide. 
The reaction mixture was stirred at 25 oC for 30 min under an open-air atmosphere at which time 
the solution had changed from green to red in color. The reaction mixture was then quenched 
with 15 mL of water. The product was extracted with two 20-mL portions of ethyl acetate. The 
organic phase was washed with 15 mL of brine, dried over anhydrous Na2SO4 and concentrated 
under diminished pressure. The residue was purified on a silica gel column (20 × 1 cm). Elution 
with 3:2 hexane-ethyl acetate afforded 31 as a red solid: yield 0.06 g (15%); silica gel TLC Rf  
0.50 (3:2 hexane-ethyl acetate); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 5 Hz), 1.30 (m, 11H), 1.68 
(m, 8H), 2.64 (t, 2H, J = 7.5 Hz), 2.95 (s, 3H), 6.68 (s, 1H), 6.85 (dd, 1H, J = 10 Hz), 6.92 (s, 
1H), 7.55 (d, 1H, J = 10 Hz) and 7.68 (s, 1H); 13C NMR (CDCl3) δ 14.2, 22.7, 24.1, 26.2, 29.3, 
29.4, 29.7, 30.3, 30.6, 31.9, 53.5, 114.1, 119.1, 123.0, 134.0, 135.01, 135.03, 135.4, 138.0, 139.6, 
143.6, 156.1 and 182.3; mass spectrum (APCI), m/z 409.2309 (M+H)+  (C25H32N2OS requires 
409.2308); ultraviolet/visible spectrum λmax 542.5 nm (CH2Cl2), λmax 556 nm (MeOH).  
 
7-(Diethylamino)-2-undecyl-3H-phenothiazin-3-one (33). To a solution of 0.27 g (0.54 mmol) 
of 32 in 14 mL of 6:1 tetrahydrofuran-water was added 0.03 g (0.54 mmol) of potassium 
hydroxide. The reaction mixture was stirred at 25 oC for 30 min under an open-air atmosphere at 
which time the solution had changed from green to red in color. The reaction mixture was then 
quenched with 15 mL of water. The product was extracted with two 20-mL portions of ethyl 
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acetate. The organic phase was washed with 15 mL of brine, dried over anhydrous Na2SO4 and 
concentrated under diminished pressure. The residue was purified on a silica gel column (20 × 1 
cm). Elution with 1:1 hexane-ethyl acetate afforded 33 as a red solid: yield 0.01 g (6%); silica 
gel TLC Rf  0.50 (1:1 hexane-ethyl acetate); 
1H NMR (CDCl3) δ 0.87 (t, 3H, J = 10 Hz), 1.09 (t, 
5H, J = 10 Hz), 1.25 (s, 17H), 1.68 (m, 3H), 2.67 (t, 2H, J = 10 Hz), 3.16 (m, 3H), 6.72 (d, 1H, J 
= 5 Hz), 6.89 (dd, 1H, J = 2.5 Hz), 6.97 (s, 1H), 7.59 (d, 1H, J = 10 Hz) and 7.72 (s, 1H); 13C 
NMR (CDCl3) δ 12.5, 14.2, 22.8, 29.4, 29.62, 29.69, 29.77, 29.79, 30.1, 31.2, 32.0, 46.8, 116.0, 
119.2, 122.6, 134.1, 135.0, 135.4, 135.5, 139.0, 139.7, 143.7, 153.8 and 182.4; mass spectrum 
(APCI), m/z 439.2766 (M+H)+  (C27H38N2OS requires 439.2778); ultraviolet/visible spectrum 
λmax 548.5 nm (CH2Cl2), λmax 605 nm (MeOH).   
 
1-(3,7-Bis(dimethyamino)-2-hexadecyl-10H-phenothiazin-10-yl)ethan-1-one (54). To a 
solution containing 0.98 g (1.54 mmol) of 22 in 9 mL of anhydrous ethanol was added in 
portions 0.12 g (3.17 mmol) of sodium borohydride keeping the reaction vessel in ice. The 
reaction mixture was stirred at 40 oC for 1 h. The resulting light green suspension was cooled to 
5 oC in an ice-water bath and filtered under an atmosphere of argon. The resulting residue was 
washed twice with ethanol and used directly for the next step without further purification. The 
crude residue was treated with 5 mL of acetic anhydride and 2 mL of pyridine. The reaction 
mixture was stirred at 120 oC for 18 h. The crude product solution, cooled to room temperature, 
was poured carefully into an ice-water bath with continuous stirring giving a brown solid. The 
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crude solid was filtered using a Buchner funnel apparatus and washed twice with water. The 
residue was purified on a silica gel column (20 × 1 cm). Elution with 9:1 hexane-ethyl acetate 
afforded a colorless oil: yield 0.04 g (4%); silica gel TLC Rf 0.50 (9:1 hexane-ethyl acetate); 
1H 
NMR (CDCl3) δ 0.88 (t, 3H, J = 5 Hz), 1.26 (s, 28H), 1.61 (m, 3H), 1.21 (s, 3H), 2.65 (s, 5H), 
2.94 (s, 6H), 6.62 (d, 1H, J = 5 Hz), 6.71 (s, 1H), 7.00 (d, 1H, J = 10 Hz), 7.08 (s, 1H), 7.30 (d, 
1H, J = 5 Hz); 13C NMR (CDCl3) δ 14.2, 22.8, 23.1, 29.3, 29.4, 29.5, 29.67, 29.69, 29.76, 29.78, 
29.82, 29.83, 30.5, 30.6, 31.4, 32.0, 35.6, 40.7, 45.20, 45.22, 110.7, 111.0, 118.5, 126.7, 127.23, 
127.24, 127.5, 136.5, 139.7, 142.0, 149.1, 169.8, 169.9; mass spectrum (APCI), m/z 552.3985 
(M+H)+ (C34H53N3OS requires 552.3982). 
 
2-Hexadecyl-N3,N3,N7,N7-tetramethyl-10H-phenothiazine-3,7-diamine dihydrochloride 
(reduced form of 22). A sample containing 0.04 g (0.07 mmol) of 54 was dissolved in 1.60 mL 
of 5 N aqueous hydrochloric acid. The resulting solution was stirred 120 oC for 30 min. The 
product solution was concentrated to dryness by lyophilization to afford the reduced form of 22 
as a light green solid: yield 0.02 g (50%). mass spectrum (APCI), m/z 534.3849 (M+Na)+ 
(C34H53N3OS requires 534.3852).    
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CHAPTER 3 
MULTIFUNCTIONAL RADICAL QUENCHERS AND THEIR ELECTROCHEMICAL 
ANALYSIS 
3.1. Introduction 
 Mitochondria are essential for eukaryotic cell survival because of their ability to produce 
ATP sufficient for essential cell functions.1 An impaired mitochondrial respiratory chain not only 
hinders ATP production but also accelerates the production of ROS.3 Copious amounts of ROS 
in the mitochondria render the natural enzymatic and non-enzymatic antioxidants insufficient to 
suppress the ensuing oxidative stress.34-40 Oxidative damage to cellular macromolecules like 
proteins, lipids and DNA result in cell apoptosis. These degenerative processes are the proximate 
cause of several mitochondrial diseases such as Friedreich’s ataxia and Alzheimer’s disease.41 In 
this context, it is imperative to develop antioxidants enabling oxidative damage suppression and 
consequent improvements in mitochondrial function, bioenergetics, adequate levels of energy 
production and overall cell health. 
Coenzyme Q10 based antioxidants have been synthesized previously (Figure 1.10). CoQ10 itself 
cannot be used as an exogenous therapeutic agent because of its extreme hydrophobicity (Log P 
> 1020) and consequent poor bioavailability.84 Again, the mitoquinone (mitoQ) based compounds 
with varying lipophilicities have been investigated. Targeting the mitochondria using the 
positively charged mitoQs was strategically correct because the mitochondria is negatively 
polarized on the inside (~150 – 170 mV negative inside). However, the accumulation of such 
positively charged species inside the mitochondria caused depolarization of the mitochondrial 
membrane potential resulting in severe hindrance to OX-PHOS and ATP production.85-87 In 
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addition, idebenone, promising enough to reach clinical trials, turned out to be an inhibitor of 
complex I, similar to rotenone.56 Therefore, none of the unnatural antioxidants based on a CoQ10 
has yet been good enough to be used as medicine for the therapy of mitochondrial diseases. 
Synthetic antioxidants having a phenolic -OH group similar to α-tocopherol (Figure 1.11) also 
showed moderate antioxidant potencies. Therefore, it is imperative to identify phenolic -OH 
based synthetic unnatural antioxidants.  
In this chapter, we describe the synthesis of a pair of pyrimidinol based regio-isomers lacking 
any substituents ortho and para to the essential phenolic -OH group and having a sixteen carbon 
side chain (Figure 3.1).  
 
Figure 3.1. The pyrimidinol based regio-isomers.  
The above pair of MRQs were biochemically compared with another pair of MRQs previously 
synthesized in our lab (Figure 3.2).  
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Figure 3.2. The pyrimidinol based MRQs for comparison. The numbering of the ring carbon 
atoms has been shown. 
Moreover, judging from the superior potency of the 2-alkoxy-4-alkylamino substituted 
compound as compared to the 4-alkoxy-2-alkylamino compound in quenching ROS, we have 
proposed the involvement of an ortho-iminoquinone intermediate (Figure 3.3) as electron 
carriers inside the mitochondria.  
 
Figure 3.3. The proposed ortho-iminoquinone intermediate for the ETC transport. 
Finally, in our efforts to understand the mechanism by which MRQs act inside the mitochondria, 
we have performed the electrochemical analysis of two pyrimidinol based MRQ redox cores in 
comparison with coenzyme Q0. The structures of the redox cores are shown in Figure 3.4 below. 
 
Figure 3.4. Two MRQ redox cores and CoQ0. 
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In the literature, the mitochondrial respiratory chain is thought to employ two-electron transport.3 
However, ROS (superoxide) production caused by electron leakage is caused by a one-electron 
transfer.3 In this Chapter, we have made an attempt to determine the mechanism by which MRQs 
are able to quench lipid peroxidation, suppress ROS, maintain mitochondrial inner membrane 
potential and augment ATP production.  
Specifically, we have attempted to investigate whether the ETC can act as a one-electron conduit 
and whether MRQs which produce an ortho-iminoquinone intermediate inside the mitochondria 
are able to support ATP production.  
Again, we have studied the possible link between the quenching of both lipid peroxidation and 
superoxide by MRQs. The hypothetical link between lipid peroxidation and superoxide 
quenching is shown in Figure 3.5. 
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Figure 3.5. Hypothetical dual role of MRQs. 
3.2. Results 
Synthesis of MRQs 
In our efforts to optimize novel pyrimidinol based antioxidants to boost biological activity, a pair 
of regio-isomers were synthesized (Figure 3.1). The syntheses of both the compounds involved a 
hydroboration-oxidation reaction as the key step.  
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For the synthesis of the regio-isomer 57, 2-chloro-4-methylpyrimidine was used as the starting 
molecule. Nucleophilic substitution of the chloro substituent by azetidine afforded 59 in 31% 
yield. Addition of the long alkyl side chain to the methyl group of 59 was carried out using n-
BuLi as the carbanion generator followed by treatment with 1-bromo pentadecane, affording an 
intermediate compound which was used directly for the next step without further purification. 
Aromatic bromination of the intermediate compound using N-bromosuccinimide afforded 
compound 60 in 8% yield for two steps. Hydroboration-oxidation of 60 by treatment with n-
BuLi, trimethyl borate and finally hydrogen peroxide afforded the final compound 57 in 56% 
yield (Scheme 3.1).71  
 
Scheme 3.1. Synthetic route employed for compound 57.   
For the synthesis of the regio-isomer 58, 4-chloro-6-methylpyrimidine was used as the starting 
molecule. Nucleophilic substitution of the chloro substituent by azetidine afforded 61 in 76% 
yield.71 Addition of the long alkyl side chain to the methyl group of 61 was carried out using n-
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BuLi as the carbanion generator followed by treatment with 1-bromo pentadecane affording 62 
in 24% yield. Aromatic bromination of compound 62 using N-bromosuccinimide afforded 
compound 63 in 20% yield. Hydroboration-oxidation of 63 by treatment with n-BuLi, trimethyl 
borate and finally hydrogen peroxide afforded the final compound 58 in 28% yield (Scheme 
3.2).71    
 
Scheme 3.2. Synthetic route employed for compound 58.   
Biochemical evaluation of MRQs 
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Figure 3.6. Structures of MRQs tested in biochemical assays 
ATP assay 
 
Figure 3.7. Total ATP levels in FRDA lymphocytes following incubation with test compounds 
for 48 h in glucose free media (25 mM galactose) to force the cell on OXPHOS. Results are 
expressed as percentage of total ATP relative to untreated control. The experiment was done by 
Dr. Omar Khdour. 
The total cellular ATP levels were measured in the presence of the synthesized MRQs using 
FRDA cells. Compound 58 could not support ATP production at higher concentrations. 
Compounds 55, 56 and 57 were able to augment ATP production at all four concentrations tested 
(Figure 3.7). 
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Reactive Oxygen Species 
 
Figure 3.8. Flow cytometric analysis of FRDA lymphocyte cells stained with 
dichlorodihydrofluorescein diacetate (DCFH-DA) for 25 min, following pretreatment with the 
test compounds for 16 h, and subsequent treatment with diethyl maleate (DEM) for 80 min to 
induce the production of ROS by depleting glutathione. The experiment was done by Dr. Omar 
Khdour. 
The ability of all four MRQs to quench ROS were tested. The results showed that compound 56, 
which is a 2-alkoxy-4-alkylamino derivative based on a pyrimidinol scaffold, was able to quench 
ROS more than the other compounds even at the lowest concentration tested (Figure 3.8). 
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Cyclic voltammetry 
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Figure 3.9. Cyclic voltammograms (CVs) of three MRQs, all at 1.0 mM concentration. 
Comparison of the CVs of CoQ0 (red trace) and the redox cores of MRQ D (blue trace) and 
MRQ A (black trace), at a scan rate 0.1 V/sec.  
Cyclic voltammetric analysis of MRQ A and MRQ D in comparison with CoQ0 shows that while 
both CoQ0 and MRQ D are functionally reversible, MRQ A is irreversible. Moreover, the total 
current produced by the redox cycling of CoQ0 is double that produced by the redox cycling of 
MRQ D (Figure 3.9). 
113 
 
2.0 1.5 1.0 0.5 0.0
-5.0x10
-6
-4.0x10
-6
-3.0x10
-6
-2.0x10
-6
-1.0x10
-6
0.0
1.0x10
-6
N N
OH
O
N
M RQ D Core
C
u
rr
e
n
t 
/ 
1
e
-6
 A
m
p
e
re
Potential / Volt
 
Figure 3.10. CV of MRQ D at 1.0 mM concentration, extending the oxidative scan to 1.8 V (red 
trace) at a scan rate of 0.02 V/sec. 
At higher potentials, the CV of MRQ D showed a second redox cycle (Figure 3.10).  
3.3. Discussion 
The starting molecule for the synthesis of regio-isomer 57 was 2-chloro-4-methylpyrimidine. 
The nucleophilic substitution reaction affording 59 proceeded in a moderate yield. Cu(I)I was 
used as a heterogeneous catalyst for this reaction. On completion of the reaction, it had to be 
removed by filtration through celite. Treatment of 59 with n-BuLi generated a carbanion at the 
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methyl carbon. Subsequent treatment with pentadecyl bromide afforded an intermediate with a 
16-carbon long aliphatic side chain. The intermediate was brominated on the aromatic ring using 
NBS affording compound 60 in a low yield. The intermediate was not isolated and characterized 
because it was an unstable compound and had to be brominated immediately after its formation. 
The aromatic bromination reaction had to be carried out in the dark. Presence of light would 
likely have caused the unwanted allylic bromination instead of the desired aromatic bromination. 
The final step of the synthesis involved a hydroboration-oxidation step affording compound 57 
in moderate yield. The role of n-BuLi in this reaction is the removal of the bromo substituent 
from compound 60. 
The starting molecule for the synthesis of regio-isomer 58 was 4-chloro-6-methylpyrimidine. 
The reaction sequence for the synthesis of compound 58 was basically the same as that of 
compound 57. However, in this scheme (Scheme 3.2) the intermediate compound 62 was found 
to be stable and hence could be isolated and characterized. In addition, the purification of the 
final compound 58 was challenging. The usual column chromatography was not enough to purify 
the compound and so preparative TLC had to be used for purification. The yields for all the steps 
in this scheme were moderate. 
While comparing the intermediates and final compounds for both the schemes by the analytical 
TLC method, it was found that the intermediates and final compound in Scheme 3.1 (compounds    
59, 60 and 57) were less polar than their counterparts in scheme 3.2 (compounds 61, 62, 63 and 
58).     
The FRDA cells used for the ATP assay were grown on galactose. Cells grown on a glucose-free 
media are forced to rely solely on mitochondrial OX-PHOS for their ATP, which makes the cells 
more vulnerable to mitochondrial perturbation.41 The results showed that only compound 58 
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which did not have any substituent at the 2-position, was not able to augment ATP production 
(Figure 3.7). 
DEM treated cells were used for the ROS assay. Treating the cells with DEM enhances ROS 
production by depletion of the natural antioxidant glutathione.41 ROS was measured based on 
ROS-induced formation of the highly fluorescent product DCF from the non-fluorescent dye 
DCFH-DA.41 The highest potency of the 2-alkoxy-4-alkylamino derivative (compound 56) 
(Figure 3.8) to quench ROS suggested to us that the antioxidant mode of action inside the 
mitochondria might be involving an ortho-iminoquinone intermediate. However, compound 58 
which also possesses an ortho-alkylamino substituent did not work as well as compound 56. The 
reason might be because compound 58 forms dimers inside cells due to the lack of a substituent 
at the 2-position which hampers its ROS quenching activity.  
The CV analysis results obtained for MRQ A and MRQ D in comparison with CoQ0 revealed 
that MRQ A can undergo only a single oxidation event between the potential range of 0.60 to 
0.80 V. Most likely, after it gets oxidized it forms an unstable species which cannot be reduced 
back. Therefore, there is reason to believe that MRQ A most probably will not be a potent 
antioxidant. In contrast, MRQ D which shows full reversibility at a potential of 0.40 V is 
expected be a more potent antioxidant (Figure 3.9). In addition, in the case of CoQ0 both the 
reduction and the oxidation events involve two electrons. In contrast, because of the exact half 
size of the total measured current, it can be argued that both the reduction and the oxidation 
events for MRQ D involve a single electron. This argument can be supported by the CV shown 
in Figure 3.10. At higher potentials (between 1.20 to 1.50 V) MRQ D undergoes its second redox 
event. 
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In conclusion, compound 56 which is a 2-alkoxy-4-alkylamino derivative of the pyrimidinol 
scaffold proved to be the best ROS quencher. That observation prompted us to put forward the 
argument that an ortho-iminoquinone intermediate is involved in the functioning of the MRQs 
inside the mitochondria. However, since compound 58 which also possesses an ortho alkyl 
amine did not perform well as an antioxidant, more structural optimization of the MRQs need to 
be done. Again, judging from the CVs it can be concluded that MRQ D should be a better 
antioxidant than MRQ A because of its ability to act reversibly. Also, MRQ D involves two 
single-electron redox events in comparison to CoQ0’s single two-electron redox event. This 
observation supports our hypothesis of the catalytic cycle of MRQ (Figure 3.5).           
3.4. Experimental section 
Reagent grade chemicals and solvents were purchased from Sigma-Aldrich Chemicals and were 
used without further purification. All the reactions were performed under an argon atmosphere. 
Thin layer chromatography (TLC) plates (precoated glass plates with silica gel 60 F254, 0.25 
mm thickness) were used for analytical TLC and were visualized by UV irradiation (254 nm). 
Flash chromatography was carried out using Silicycle 200−400 mesh silica gel. 1H and 13C NMR 
spectra were obtained using a Varian 500 MHz NMR spectrometer. Chemical shifts (δ) are 
reported in parts per million (ppm) and are referenced to residual CHCl3 (δ 7.26 ppm for 1H 
NMR and δ 77.16 for 13C NMR) as the internal standard. Splitting patterns are designated as s, 
singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublet; m, multiplet. High resolution mass 
spectra were obtained at the Arizona State University CLAS High Resolution Mass Spectrometry 
Facility. 
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2-(Azetidin-1-yl)-4-methylpyrimidine (59). To a stirred solution containing 0.20 g (1.55 mmol) 
of 2-chloro-4-methylpyrimidine in 8 mL of anhydrous dimethylformamide was added 1.01 g 
(3.11 mmol) of cesium carbonate and 0.29 g (3.11 mmol) of azetidine hydrochloride. The 
reaction mixture was then treated with 0.04 g (0.15 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline and 0.03 g (0.15 mmol) of copper(I)iodide and the resulting mixture was stirred 
at 50 oC for 12 h. After the reaction was complete, the reaction mixture was diluted in 20 mL of 
ethyl acetate and filtered through Celite. The filtrate was concentrated under diminished 
pressure. The residue was purified by column chromatography on a silica gel column (20 × 1 
cm). Elution with 1:3 hexane-ethyl acetate afforded 59 as a yellowish oil: yield 0.08 g (31 %); 
silica gel TLC Rf 0.29 (1:1 hexane-ethyl acetate); 
1H NMR (CDCl3) δ 2.27 (m, 5H), 4.07 (t, 4H, 
J = 7.5 Hz), 6.29 (d, 1H, J = 5 Hz) and 8.07 (d, 1H, J = 5 Hz); 13C NMR (CDCl3) δ 16.2, 24.2, 
50.0, 109.5, 157.2, 162.8 and 167.6; mass spectrum (EI), m/z 149.0958 (M)+ (C8H11N3 requires 
149.0953). 
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2-(Azetidine-1-yl)-5-bromo-4-hexadecylpyrimidine (60). A stirred solution containing 0.28 g 
(1.85 mmol) of 59 in 7 mL of freshly distilled THF was cooled to _78 oC and maintained under 
argon for 15 min. A solution containing 0.80 mL (0.54 g, 1.99 mmol) of 2.5 M n-BuLi in hexane 
was added dropwise and the resulting reaction mixture was stirred at _78 oC for 1 h. A solution 
containing 0.60 mL (0.60 g, 1.85 mmol) of 1-bromopentadecane was then added dropwise and 
the resulting mixture was warmed to 0 oC and stirred for 1 h. The reaction was quenched by the 
addition of 30 mL of saturated aq. NH4Cl and extracted with two 50-mL portions of CH2Cl2. The 
combined organic phase was dried over MgSO4 and concentrated under diminished pressure. 
The crude residue was used directly for the next step without further purification. To a stirred 
solution containing 0.09 g (0.25 mmol) of the crude residue in 4 mL of anhydrous 
dichloromethane, 0.05 g (0.25 mmol) of recrystallized N-bromosuccinimide was added in the 
dark and the reaction mixture was stirred for 1 h at room temperature. The solvent was 
concentrated under diminished pressure. The residue was purified by column chromatography on 
a silica gel column (20 × 1 cm). Elution with 4:1 hexane-ethyl acetate afforded 60 as a colorless 
solid: yield 0.07 g (8% for two steps); silica gel TLC Rf 0.50 (4:1 hexane-ethyl acetate); 
1H NMR 
(CDCl3) δ 0.87 (t, 1H, J = 7.5 Hz), 0.93 (t, 5H, J = 7.5 Hz), 1.25 (s, 6H), 1.40 (m, 4H), 1.64 (m, 
4H), 2.32 (m, 4H), 2.44 (s, 4H), 2.72 (t, 3H, J = 7.5 Hz), 4.09 (t, 8H, J = 7.5 Hz) and 8.20 (s, 
1H); 13C NMR (CDCl3) δ 14.0, 16.3, 22.6, 25.3, 27.6, 29.50, 29.55, 29.6, 29.78, 29.79, 29.81, 
29.82, 29.84, 29.9, 32.0, 37.1, 50.5, 108.6, 158.5, 161.2, 165.7 and 168.8; mass spectrum 
(APCI), m/z 438.2453 (M+H)+ (C23H40BrN3 requires 438.2478). 
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2-(Azetidine-1-yl)-4-hexadecylpyrimidin-5-ol (57). A stirred solution containing 0.04 g (0.09 
mmol) of 60 in 2 mL of freshly distilled THF was cooled to _78 oC and maintained under argon 
for 10 min. To the resulting suspension was added 0.04 mL (0.03 g, 0.09 mmol) of a 2.5 M 
solution of n-BuLi in hexane and the resulting reaction mixture was stirred at _78 oC for 1 h, 
resulting in a clear yellow solution. To the resulting solution was added slowly 0.02 mL (0.02 g, 
0.17 mmol) of trimethyl borate and the reaction mixture was maintained at 0 oC for 1 h. A 
solution of 0.12 mL of hydrogen peroxide (30 % v/v) was then added to the reaction mixture 
which was allowed to warm to room temperature and stirred for 30 min. The reaction mixture 
was then diluted by the addition of 10 mL of saturated aqueous ammonium chloride solution and 
extracted with two 15-mL portions of dichloromethane. The combined organic phase was dried 
(MgSO4) and concentrated under diminished pressure. The residue was purified by column 
chromatography on a silica gel column (20 × 1 cm). Elution with 2:3 hexane-ethyl acetate 
afforded 57 as a colorless solid: yield 0.02 g (56%); silica gel TLC Rf 0.50 (2:3 hexane-ethyl 
acetate); 1H NMR (CDCl3) δ 0.87 (t, 3H, J = 5 Hz), 1.25 (s, 22H), 1.64 (m, 3H), 2.32 (t, 4H, J = 
7.5 Hz), 2.68 (t, 2H, J = 7.5 Hz), 4.11 (t, 5H, J = 7.5 Hz) and 7.69 (s, 1H); mass spectrum 
(APCI), m/z 376.3309 (M+H)+ (C23H41N3O requires 376.3322).  
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4-(Azetidin-1-yl)-6-methylpyrimidine (61). To a stirred solution containing 0.20 g (1.55 mmol) 
of 4-chloro-6-methylpyrimidine in 8 mL of anhydrous dimethylformamide was added 1.01 g 
(3.11 mmol) of cesium carbonate and 0.29 g (3.11 mmol) of azetidine hydrochloride. The 
reaction mixture was then treated with 0.04 g (0.15 mmol) of 3,4,7,8-tetramethyl-1,10-
phenanthroline and 0.03 g (0.15 mmol) of copper(I)iodide and the resulting reaction mixture was 
stirred at 50 oC for 12 h. After the reaction was complete, the reaction mixture was diluted in 20 
mL of ethyl acetate and filtered through Celite. The filtrate was concentrated under diminished 
pressure. The residue was purified by column chromatography on a silica gel column (20 × 1 
cm). Elution with 1:1 ethyl acetate-methanol afforded 61 as a yellowish oil: yield 0.18 g (76 %); 
silica gel TLC Rf 0.66 (methanol); 
1H NMR (CDCl3) δ 2.18 (s, 3H), 2.27 (m, 2H), 3.93 (t, 4H, J 
= 7.5 Hz), 5.86 (s, 1H) and 8.30 (s, 1H); 13C NMR (CDCl3) δ 16.3, 23.5, 49.5, 100.1, 157.3, 
162.3 and 163.3; mass spectrum (EI), m/z 149.0956 (M)+ (C8H11N3 requires 149.0953).  
  
4-(Azetidine-1-yl)-6-hexadecylpyrimidine (62). A stirred solution containing 0.60 g (4.03 
mmol) of 61 in 15 mL of freshly distilled THF was cooled to _78 oC and maintained under argon 
121 
 
for 15 min. A solution containing 1.80 mL (1.22 g, 4.35 mmol) of 2.5 M n-BuLi in hexane was 
added dropwise and the resulting reaction mixture was stirred at _78 oC for 1 h. A solution 
containing 1.20 mL (1.21 g, 4.03 mmol) of 1-bromopentadecane was then added dropwise and 
the resulting mixture was warmed to 0 oC and stirred for 1 h. The reaction was quenched by the 
addition of 30 mL of saturated aq. NH4Cl and extracted with two 50-mL portions of CH2Cl2. The 
combined organic phase was dried over MgSO4 and concentrated under diminished pressure. 
The residue was purified on a silica gel column (20 × 1 cm). Elution with ethyl acetate afforded 
62 as a colorless oil: yield 0.35 g (24%); silica gel TLC Rf 0.4 (ethyl acetate); 
1H NMR (CDCl3) 
δ 0.62 (t, 3H, J = 5 Hz), 1.01 (s, 26H), 1.42 (s, 2H), 2.15 (t, 2H, J = 7.5 Hz), 2.29 (t, 2H, J = 7.5 
Hz), 3.82 (s, 4H), 5.72 (s, 1H) and 8.24 (s, 1H); 13C NMR (CDCl3) δ 13.7, 16.2, 22.3, 28.4, 29.0, 
29.1, 29.2, 29.3, 29.4, 31.6, 37.5, 49.3, 99.2, 157.6, 162.3 and 167.7; mass spectrum (APCI), m/z 
360.3335 (M+H)+ (C23H41N3 requires 360.3326).  
 
4-(Azetidine-1-yl)-5-bromo-6-hexadecylpyrimidine (63). To a stirred solution containing 0.47 
g (1.31 mmol) of 62 in 15 mL of anhydrous dichloromethane was added 0.24 g (1.31 mmol) of 
recrystallized N-bromosuccinimide in the dark and the reaction was stirred for 1 h at room 
temperature. The solvent was concentrated under diminished pressure. The residue was purified 
by column chromatography on a silica gel column (20 × 1 cm). Elution with 3:2 hexane-ethyl 
acetate afforded 63 as a colorless oil: yield 0.11 g (20%); silica gel TLC Rf 0.60 (1:1 hexane-
ethyl acetate); 1H NMR (CDCl3) δ 0.83 (t, 3H, J = 7.5 Hz), 1.20 (s, 26H), 1.62 (m, 2H), 2.25 (m, 
122 
 
2H), 2.71 (t, 2H, J = 7.5 Hz), 4.36 (t, 4H, J = 7.5 Hz) and 8.31 (s, 1H); 13C NMR (CDCl3) δ 
14.1, 16.2, 22.7, 27.9, 29.42, 29.47, 29.56, 29.59, 29.6, 29.72, 29.76, 31.9, 36.9, 53.1, 101.3, 
155.4, 159.4 and 167.2; mass spectrum (APCI), m/z 438.2474 (M+H)+ (C23H40BrN3 requires 
438.2478).  
 
4-(Azetidine-1-yl)-6-hexadecylpyrimidin-5-ol (58). A stirred solution containing 0.11 g (0.30 
mmol) of 63 in 3 mL of freshly distilled THF was cooled to _78 oC and maintained under argon 
for 10 min. To the resulting suspension was added 0.25 mL (0.17 g, 0.60 mmol) of a 2.5 M 
solution of n-BuLi in hexane and the resulting reaction mixture was stirred at _78 oC for 1 h, 
resulting in a clear yellow solution. To the solution was added slowly 0.10 mL (0.09 g, 0.90 
mmol) of trimethyl borate and the reaction mixture was maintained at 0 oC for 1 h. A solution of 
7.50 mL of hydrogen peroxide (30 % v/v) was then added to the reaction mixture which was 
allowed to warm to room temperature and stirred for 30 min. The reaction mixture was then 
diluted by the addition of 20 mL of saturated aqueous ammonium chloride solution and extracted 
with two 30-mL portions of dichloromethane. The combined organic phase was dried (MgSO4) 
and concentrated under diminished pressure. The residue was purified by column 
chromatography on a silica gel column (20 × 1 cm). Elution with 4:1 ethyl acetate-methanol 
afforded 58 as a colorless solid: yield 0.03 g (28%); silica gel TLC Rf 0.50 (4:1 ethyl acetate-
methanol); 1H NMR (CDCl3) δ 0.86 (t, 3H, J = 7.5 Hz), 1.24 (s, 26H), 1.48 (s, 2H), 2.34 (m, 
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2H), 2.42 (t, 2H, J = 7.5 Hz), 4.37 (t, 4H, J = 7.5 Hz) and 8.04 (s, 1H); mass spectrum (APCI), 
m/z 376.3308 (M+H)+ (C23H41N3O requires 376.3332). 
Electrochemical analysis 
Cyclic voltammetry (CV) studies were carried out using a Model 1030 multi-potentiostat from 
CH Instruments. The platinum working electrode 2 mm diameter (model CHI102), platinum wire 
counter electrode (model CHI115), and Ag/AgCl reference electrode (model CHI111) were 
obtained from CH Instruments. Cyclic voltammetry measurements were performed in a precut 
20 mL vial at room temperature with a 3 mL solution of 0.1 M tetrabutylammonium perchlorate 
(supporting electrolyte) in acetonitrile (solvent) containing the redox core analyte at a 1 mM 
concentration. The vial was covered with a Teflon cap (CHI223) and sealed using parafilm. All 
samples were purged with nitrogen for 5 min to remove any oxygen prior to performing the 
experiment. After purging was complete, the nitrogen was moved above the sample so that only 
the headspace was streamed with nitrogen. The cell was allowed to sit for 1 min to allow the 
diffusion layer to set up and come to equilibrium. The parameters used for the starting and vertex 
potential were 2 V and _ 2 V, respectively, and the scan rate was 100 mV/s or 40 mV/s for the 
redox potential measurements. The cyclic voltammogram of the redox cores involved initial 
oxidative sweeps and that for coenzyme Q0 involved an initial reductive sweep. Between each 
CV experiment, the electrodes were rinsed with dichloromethane. The platinum working 
electrode was then rinsed with doubly distilled water and polished, first with 0.30 micron 
alumina powder followed by 0.05 micron alumina powder and doubly distilled water on a 
polishing pad (CHI120). Immediately before each CV was performed, the electrodes were rinsed 
with acetonitrile. 
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